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STRUCTURE AND FUNCTION  
ANALYSIS OF PAR-4 
 
Par-4 is a leucine zipper domain protein that induces apoptosis on its own in 
certain cancer cells and in Ras-transformed cells, but not in normal or immortalized cells.  
Par-4 induces apoptosis by activation of the Fas death receptor pathway and co-parallel 
inhibition of NF-κB transcription activity. Cells that are resistant to apoptosis by Par-4 
alone, however, are greatly sensitized by Par-4 to the action of other pro-apoptotic insults 
such as growth factor withdrawal, TNF, ionizing radiation, intracellular calcium 
elevation, or those involved in neuronal degeneration such as Alzheimer's, Parkinson's, 
Huntington's and Stroke. Previous studies have suggested that the apoptosis-sensitization 
potential of Par-4 is dependent upon inhibition of ζPKC or WT1 cell survival function by 
direct interaction between the leucine zipper domain at the carboxy-terminus of Par-4 and 
the zinc finger domains of ζPKC or WT1. In this study, I performed structure-function 
analysis using GFP-fusion proteins and deletion mutants to identify the functional 
localization and domains of Par-4 that are essential for apoptosis induction. My findings 
suggest that apoptosis by Par-4 is dependent on its translocation to the nucleus for  
induction of apoptosis. A bipartite nuclear localization signal sequence corresponding to 
amino acids 137-155 was necessary for nuclear translocation of Par-4. Importantly, the 
 
core residues 137-204 in the center part of Par-4 were necessary and sufficient to induce 
Fas pathway activation, inhibition of nuclear NF-κB transcription activity and apoptosis. 
These findings imply that binding of Par-4 via its leucine zipper domain to other proteins 
is dispensable for apoptosis by Par-4. 
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CHAPTER 1 
INTRODUCTION AND BACKGROUND 
Physiological cell death in animals, especially in development and in the immune 
system, occurs by the process of apoptosis. It allows the complete elimination of dying 
cells without causing an inflammatory response (Vaux and Korsmeyer, 1999) (Krammer, 
2000). The key defining features of apoptosis are the activation of a series of cysteine 
aspartyl proteases or caspases, the central engines of apoptosis that orchestrate cell death 
by cleaving a variety of intracellular substrates and triggering the cell demise. They are 
synthesized as inactive zymogens and are activated by proteolytic cleavage, typically 
through the action of upstream caspases. Caspase activation is followed by chromatin 
condensation and the display of phosphatidylserine on the cell surface that marks the cell 
for phagocytosis by specialized macrophage or neighboring cells, thus avoiding an 
inflammatory response (Green, 1998). Other typical features of apoptosis include 
cytoplasmic shrinkage, zeiosis (membrane blebbing) and the formation of apoptotic 
bodies with nuclear fragments. The underlying death process is designated apoptosis to 
delineate it clearly from other death programs such as accidental necrosis, apoptosis-like 
programmed cell death (PCD) and necrosis-like PCD (Leist and Jaattela, 2001). 
Two general pathways are thought to be responsible for activation of the caspase 
cascades. One such pathway is mediated by transmembrane death receptors of the CD95 
(Apo-1 or Fas)/TRAIL/tumor-necrosis factor (TNF) receptor 1 family, whose ligation 
triggers recruitment and assembly of multi-protein complexes to activate the upstream 
caspase 8 (Ashkenazi and Dixit, 1998). The other principal death-signaling pathway 
involves the mitochondria, which act in response to multiple death insults by releasing 
cytochrome c into the cytosol. Once released, cytochrome c will induce the assembly of 
an intracellular apoptosome complex that recruits and activates caspase 9 via the adaptor 
protein Apaf-1 (Zou et al., 1997). Activation of caspase 8 or caspase 9 triggers the 
activation of effector caspases, such as caspase 3, that are involved in survival substrate 
degradation and nucleosomal DNA fragmentation (Thornberry and Lazebnik, 1998). The 
apoptotic pathways are counteracted by survival signaling pathways, which may act by 
stabilizing the mitochondrial function and integrity and suppressing release of 
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cytochrome c or by interfering with the assembly of the death receptor complexes and 
inhibiting upstream caspases (Evan and Vousden, 2001). 
Apoptosis is a critical process that evolved to regulate development, immunity 
and to protect multicellular organisms from the accumulation of damaged cells. 
Apoptosis is achieved through complex mechanisms that should be tightly regulated 
because defects in the suppression of programmed cell death can result in an uncontrolled 
loss of essential cells giving rise to diverse diseases like neurodegenerative disorders, 
AIDS, ischemia and repercussion injury. On the other hand, accumulation of cells 
harboring serious mutation or unwanted traits by inhibition of apoptosis leads to disorders 
like cancer and autoimmune diseases (Thompson, 1995).  
Apoptosis in cancer. Paradoxically, increased cell proliferation driven by 
activation of oncoproteins (such as Myc, E1A and E2F) or inactivation of tumor-
suppressor proteins (such as retinoblastoma protein) is often associated with accelerated 
apoptosis. Thus, the coupling between cell division and cell death is thought to act as a 
barrier that cells need to overcome for cancer initiation and progression. This may be the 
underlying reason why cancer cells often show a high expression of anti-apoptotic 
proteins such as Bcl-2, Bcl-xL, survivin or Bcr-Abl along with inactivation of pro-
apoptotic tumor-suppressor proteins p53, p19arf or PTEN that control apoptosis pathways 
generating severe defects in the balance between cell division and programmed cell death 
in cancer settings. The genetic abnormalities that generate defects in apoptotic pathways 
allow cancer cells to survive. Interestingly, despite the severe disruption of the classic 
apoptosis pathways, cancer cells retain at least some molecular components necessary for 
apoptosis (Leist and Jaattela, 2001).  
Various chemical, hormonal, and radiation treatments, cause irreparable cellular 
damage that triggers apoptosis in cancer cells. Consequently, the success of cancer 
treatment depends not only on its ability to induce irreparable cellular damage but also on 
the ability to respond to the damage by activation of the apoptotic machinery. Mutations 
in apoptotic pathways may result in resistance to drugs and radiation. Such mutations can 
be used to predict resistance to different therapeutic approaches and, consequently serve 
as new treatment targets (Sjostrom and Bergh, 2001). The challenge is to identify and 
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understand the molecular mechanisms involved in tumor progression and to develop anti-
cancer therapies that directly attack key survival mechanisms (Evan and Vousden, 2001). 
Apoptosis in neurons. It is believed that increased apoptosis in one or more 
populations of neurons is behind the development of neurodegenerative diseases such as 
Alzheimers, Parkinsons, Huntingtons and stroke. Studying apoptosis mechanisms in 
neurons is just as challenging as in other cell types and organs. But contrary to the goal of 
dissecting these mechanisms in the development of malignancies, in neurons apoptosis 
inhibitory pathways are sought. While apoptosis is a natural process that is required for 
normal development of the nervous system, its reactivation later in life is pathological. In 
the nervous system, different neurological disorders arise from degeneration and death of 
neurons. Neurons are long-lived cells that do not undergo active regeneration. Indeed, it 
is suggested that even when apoptosis is activated in neurons, it is counteracted by 
responses that slow or reverse this process. Neurotrophic factors have been identified that 
can protect neurons by activation of survival proteins such as NF-κB (Mattson and 
Camandola, 2001). 
Prostate apoptosis response-4, Par-4, a pro-apoptotic protein, was found to play a 
critical role in a number of cancer and neurodegenerative disease paradigms. While its 
pro-apoptotic role in cancer cells should be enhanced, approaches to inhibit Par-4 
expression or function need to be explored in neurons. In this chapter I will discusses the 
identification, characterization, and the current view of the mechanism of action of Par-4 
in various diseases and its potential in molecular therapeutics.  
Identification and expression of Par-4 
Prostate cancer is conventionally treated by androgen ablation, which shows an 
initial response in about 80% of the cases. Unfortunately, only the androgen-dependent 
cancer cells are affected by this treatment. Androgen-independent cancer cells, which 
may constitute part of the tumor, are not eliminated, leading to relapse of the disease. Par-
4 was first identified in an experiment designed to find common apoptotic genes induced 
in response to apoptotic insults in androgen-dependent and -independent prostate cancer 
cells (Sells et al., 1994). Androgen-dependent cells undergo apoptosis upon withdrawal 
of androgen by a process involving elevation of intracellular calcium (Kyprianou et al., 
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1990) and de novo gene expression and protein synthesis (Connor et al., 1988). Androgen 
ablation is unable to cause elevation of intracellular calcium levels or apoptosis in 
androgen-independent cancer cells. However, forced elevation of intracellular calcium, 
using the ionophore ionomycin, can cause apoptosis in the androgen-independent rat 
prostate cancer cell lines (Martikainen et al., 1991). These facts were utilized to identify 
the par-4 gene by differential hybridization between rat AT-3 androgen-independent 
prostate cancer cells that were either unexposed or exposed to ionomycin with 
cycloheximide (Sells et al., 1994). The use of the translation inhibitor cycloheximide 
ensured the isolation of first line of genes transcribed in response to calcium elevation in 
androgen-independent prostate cancer cells. Induction of par-4 was apoptosis-specific; it 
was induced only by apoptotic inducers and not by growth stimulating, growth arresting, 
necrotic or stress stimuli in epithelial and fibroblast cells. 
Par-4 was later rediscovered in human cells as a binding partner of the Wilms' 
tumor 1 (WT1) (Johnstone et al., 1996) and atypical protein kinase C (aPKC) (Diaz-
Meco et al., 1996). Human Par-4 was found to localize to chromosome 12q21, a region 
that is reorganized in Wilms tumorigenesis (Johnstone et al., 1998). This chromosomal 
defect occurs as frequently as the known WT1 deletions on chromosome 11 (Austruy et 
al., 1995). In addition, it has been shown that loss of genetic material around this region 
is also involved in human male germ cell tumor development (Murty et al., 1996). Given 
the role of WT1 in development of the urogenital system, this also can be related to an 
abnormal expression of par-4. 
Par-4 is detected in almost all rat tissues with varying degrees of expression. It is 
detected in cells originating from endoderm, mesoderm, or ectoderm. Thus, Par-4 is not 
likely involved in lineage determination during differentiation of the germinal embryonic 
layers. However it is not expressed in certain neurons and medulla of adrenal gland from 
ectodermal origin and dense connective tissue, lymphocytes and some smooth muscle 
cells of mesodermal origin when examined by immunohistochemical analysis (Boghaert 
et al., 1997). It is important to note that Par-4 can be detected in lymphocytes by Western 
blot analysis, suggesting its presence in low levels in these cells. Consistent with its pro-
apoptotic functions, Par-4 levels are generally higher in dying cells; for example, in 
prostate ductal cells of castrated rats, degenerating neurons and in the web area between 
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the digits in the developing limb bud of a 14.5 day mouse embryo. Par-4 was also found 
to be ubiquitously expressed in all tissues of humans, mice, horses, pigs and cows. 
In addition to its widespread presence in mammalian tissues, Par-4 was found in 
other vertebrates including fish, birds and Xenopus. Another interesting occurrence of 
Par-4 is in the involuting tadpole tail. A tadpole goes through three different stages: pre-
metamorphosis, pro-metamorphosis and finally metamorphosis when the tail shrinkage 
begins. Par-4 expression in the tail is low in the first two stages but it is up-regulated in 
the metamorphosis phase, indicating that Par-4 is involved in apoptosis of the shrinking 
tail (Rangnekar, 2001). 
The identification of the rat par-4 cDNA was followed by that of human par-4 
cDNA (Johnstone et al., 1996) (Diaz-Meco et al., 1996). Although it was known for a 
long time that mice express Par-4 protein that is cross-immunoreactive with the rat Par-4 
antibody (Johnstone et al., 1996), the mouse par-4 cDNA has not yet been identified. 
Using the mouse EST database published in the GenBank (NCBI Web site), I constructed 
a contiguous cDNA sequence for mouse par-4. DNA sequence analysis of par-4 in all 
three species showed very high sequence homology. Rat and mouse par-4 cDNA show 
92.2% homology. The protein sequences have a homology of 93%. Comparison between 
rat and human Par-4 proteins shows high homology as well, about 75% identical and 
84% functionally similar amino acids. In addition to the general high homology found 
between the three known Par-4 sequences, a more detailed examination revealed 
significant similarities between different domains. All areas of putative functional 
importance are 100% identical in all three species (Fig. 1.1).  
It is interesting to note that, although the par-4 gene from other vertebrates has 
not been cloned, it is expected to share high similarities with rat Par-4 since the proteins 
are recognized by the anti-rat Par-4 antibody. In addition, the high conservation of Par-4 
sequence in the rat, human and mouse implies a significant biological role for Par-4 
common to many species, making the search for its exact physiological function(s) even 
more important. 
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Figure 1.1: Protein sequence alignment of human, rat and mouse Par-4 showing 
the high degree of conservation of Par-4 in all three species. Red letters denote identical 
sequence. 
In the gray highlighted consensus line:  
Upper case = identical amino acids in all three species. 
Lower case = Same amino acids in two of the species. 
# = Asparagine, glutamine, aspartic or glutamic acid. 
! = Valine or isoleucine. 
 = No similarities. 
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Figure 1.1: Protein sequence alignment of human, rat and mouse Par-4 
             1                                                   50 
      Human  MATGGYRTSS GLGGSTTDFL EEWKAKREKM RAKQNPPGPA PPGGGSSDAA 
        Rat  MATGGYRSS. ..GSTT.DFL EEWKAKREKM RAKQNPVGPG SSGG...DPA 
      Mouse  MATGGYRSG. ..GSTTTDFL EEWKAKREKM RAKQNPAGPG SSGG...DPA 
  Consensus  MATGGYRss. ..GstTtDFL EEWKAKREKM RAKQNP.GPg ssGG...DpA 
 
             51                                                 100 
      Human  GKPPAGALGT PAAAAANELN NNLPGGAPAA PAVPGPGGVN CAVGSAMLTR 
        Rat  AKSPAGPLAQ TTAAGTSELN HG.PAGA.AA PAAPGPGALN CAHGSSALPR 
      Mouse  AKSPAGSLTP TAVAGTSELN HG.PAGA.AA PAAPAPGALN CAHGSSTLPR 
  Consensus  aKsPAG.L.. taaAgtsELN hg.PaGA.AA PAaPgPGalN CAhGSs.LpR 
 
             101                                                150 
      Human  APPARGPRRS EDEPP.AASA SAAPPPQRDE EEPDGVPEKG KSSGPSARKG 
        Rat  GAP..GSRRP EDECPIAAGA AGAPASRGDE EEPDSAPEKG RSSGPSARKG 
      Mouse  AAP..GSRRA EDECPSAAAA SGAPGSRGDE EEPDSAREKG RSSGPSARKG 
  Consensus  aaP..GsRR. EDEcP.AA.A sgAP.srgDE EEPDsapEKG rSSGPSARKG 
 
             151                                                200 
      Human  KGQIEKRKLR EKRRSTGVVN IPAAECLDEY EDDEAGQKER KREDAITQQN 
        Rat  KGQIEKRKLR EKRRSTGVVN IPAAECLDEY EDDEAGQKER KREDAITQQN 
      Mouse  KGQIEKRKLR EKRRSTGVVN IPAAECLDEY EDDEAGQKER KREDAITQQN 
  Consensus  KGQIEKRKLR EKRRSTGVVN IPAAECLDEY EDDEAGQKER KREDAITQQN 
 
             201                                                250 
      Human  TIQNEAVNLL DPGSSYLLQE PPRTVSGRYK STTSVSEEDV SSRYSRTDRS 
        Rat  TIQNEAASLP DPGTSYLPQD PSRTVPGRYK STISAPEEEI LNRYPRTDRS 
      Mouse  TIQNEAATLP DPGTSYLPQD PSRTVPGRYK STTSAPEDEI SNRYPRTDRS 
  Consensus  TIQNEAa.Lp DPGtSYLpQ# PsRTVpGRYK STtSapE##! snRYpRTDRS 
 
             251                                                300 
      Human  GFPRYNRDAN VSGTLVSSST LEKKIEDLEK EVVTERQENL RLVRLMQDKE 
        Rat  GFSRHNRDTS APANFASSST LEKRIEDLEK EVLRERQENL RLTRLMQDKE 
      Mouse  GFSRHNRDAN APASFSSSST LEKRIEDLEK GVVRERQENL RLVRLMQDKE 
  Consensus  GFsRhNRDan apa.f.SSST LEKrIEDLEK eVvrERQENL RLvRLMQDKE 
 
             301                                         343 
      Human  EMIGKLKEEI DLLNRDLDDI EDENEQLKQE NKTLLKVVGQ LTR 
        Rat  EMIGKLKEEI DLLNRDLDDM EDENEQLKQE NKTLLKVVGQ LTR 
      Mouse  EMIVKLQEEI DLVNRDLDDM EDENEQLKQE NKTLLKVVGQ LTR 
  Consensus  EMIgKLkEEI DLlNRDLDDm EDENEQLKQE NKTLLKVVGQ LTR 
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Structure-function analysis of Par-4 
Rat Par-4 is a 332 amino acid protein (Fig. 1.2). It has an apparent molecular 
weight of about 40 kDa on SDS-PAGE. Sequence analysis of the Par-4 sequence 
revealed a number of interesting sites and domains. One of the most interesting domains 
of Par-4 is the leucine zipper domain that spans the region between amino acids 292 to 
332 (Fig. 1.2). The primary sequence of a leucine zipper is a roughly 42-residue stretch 
having a repeated heptad (A-B-C-D-E-F-G-) with non-polar residues predominating at 
position A, leucine predominating at position D, and polar amino acids dominating the 
other positions of the repeat. This structure is packed together in a parallel alpha-helical 
coiled coil with the conserved leucine residues playing a key role. The helices are held 
together by hydrophobic interactions between leucine residues, which are located on one 
side of each helix. The hydrophobic coiled-coil facilitates homo- or heterodimerization of 
two such proteins (that may form a functional transcription factor). Examples of proteins 
containing leucine zipper domains are the DNA-binding proteins encoded by the proto-
oncogenes myc, fos, and jun. 
Par-4 has at least 5 confirmed leucine repeats in the C-terminus region  (for a 
detailed study of the leucine zipper domain of Par-4, see reference (Dutta et al., 2001)). 
As predicted by Sells et al. (Sells et al., 1994), this region was later found to mediate Par-
4 homodimerization and heterodimerization with all the binding partners identified to 
date. WT1 isoforms bind specifically to the C-terminal end of Par-4 but not to the N-
terminus (Johnstone et al., 1996). The zinc finger domains of aPKC isoforms binds 
specifically to leucine zipper region of Par-4 (Diaz-Meco et al., 1996). Dlk and p62 also 
bind to the leucine zipper domain of Par-4 (Kogel et al., 1998) (Chang et al., 2002). 
The functional significance of the leucine zipper domain is obvious since deletion 
mutant of Par-4 lacking the leucine zipper region (∆Zip) is unable to sensitize melanoma 
cells to apoptotic stimuli. Furthermore, PC12 cells expressing ∆Zip are insensitive to 
Aβ1-42 or withdrawal of trophic factors (Guo et al., 1998a).  
In addition to the leucine zipper domain, Par-4 has two putative nuclear 
localization sequences, NLS1 and NLS2 (Fig. 1.2). Both of them are localized to the N 
terminal half of the molecule. NLS1 is a short sequence of six amino acids while NLS2 is 
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a bipartite sequence. Both regions are 100% conserved in human, rat and mouse Par-4 
(Table 1.1). The presence of nuclear localization sequences raised the question of the 
localization of Par-4. At first glance, Par-4 seems to be localized in the cytoplasm. In 
PC12 cells, active Par-4 seemed to be localized in the cytoplasm (Guo et al., 1998a). No 
translocation of Par-4 was detected in NIH 3T3 mouse fibroblast cells, and removal of 
the NLS1 by deletion of the first 68 amino acids did not affect the functions of Par-4 
(Diaz-Meco et al., 1999). On the other hand, the presence of NLS2, the ability of Par-4 to 
inhibit RelA activity, and to bind Dlk and WT1 support the notion of a nuclear function 
for Par-4. 
Par-4 functions seem to be tightly regulated at both the transcriptional and post-
translational level, which may explain that despite its constitutive expression, endogenous 
Par-4 does not induce apoptosis on its own. Promoter studies are underway to dissect the 
transcription regulation of Par-4. Post-translational modification may occur through 
phosphorylation. Indeed Par-4 has a number of PKA, PKC and CKII putative 
phosphorylation sites. Some of these sites are identical in human, rat and mouse Par-4 
(Fig. 1.2, Table 1.1). Preliminary data from our group indicates that Par-4 is indeed 
phosphorylated. The sites and relevance of Par-4 phosphorylation are currently under 
investigation. 
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Figure 1.2: Schematic representation of rat Par-4 structure showing the putative 
nuclear localization sequences (NLS1 and NLS2) and leucine zipper domain. Putative 
phosphorylation sites conserved in all three species are shown as vertical black lines. The 
red line represent the phosphorylation sites that are unique to the rat sequence. The rat 
Par-4 was used in this study. 
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Figure 1.2: Schematic representation of Par-4 structure 
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Table 1.1: Common domains in human, rat and mouse Par-4. 
Sites shown in black are conserved and sites shown in gray are non-conserved in 
all three species. 
- = Site absent. 
Lower case letters = any amino acids to make up the consensus sequence. 
Parenthesis = Different amino acid in one of the species that does not change the 
consensus sequence. 
x = any amino acids 
NES = Nuclear Exclusion Sequence. 
 12
 
Table 1.1: Common domains in human, rat and mouse Par-4. 
Domains Site in rat Site in 
mouse 
Site in 
human 
Sequence 
Nuclear Localization Sequence 
(NLS1) 
20-25 21-26 24-29 KAKREK 
Nuclear Localization Sequence 
(NLS2) 
137-154 138-154 147-163 RKGKGQIEKRKLREKRR
PKA phosphorylation sites 151-154 152-155 161-164 KRrS 
 152-155 153-156 162-165 RRsT 
PKC phosphorylation sites 96-98 97-99 - SrR 
 - 125-127 - SaR 
 135-137 136-138 145-147 SaR 
 - - 225-227 SgR 
 - 231-233 240-242 Sn(s)R 
 236-238 237-239 246-248 TdR 
 - - 283-285 TeR 
CKII phosphorylation sites 11-14 12-15 15-18 S(T)ttD 
 38-41 39-42 - SggD 
 - - 110-113 SedE 
 115-118 116-119 - SrgD 
 124-127 125-128 - Sar(p)E 
 197-200 198-201 - S(T)lpD 
 223-226 224-227 - SapE 
 - - 233-236 SvsE 
 - - 235-238 SeeD 
 - - 244-247 SrtD 
 258-261 259-262 268-271 StlE 
NES 291-302 292-303 301-312 MxxxLxxxI xLx 
RGD Cell attachment sequence 116-118 117-119 - RGD 
ATP/GTP-binding site motif - - 134-141 GvpekGKS 
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Figure 1.3: Binding partners of Par-4. Par-4 interacts with WT1, ζPKC, Dlk or 
p62, following an as yet uncharacterized activation signal, to regulate cell survival and 
induce apoptosis. The relationship between the complex formation and induction of 
apoptosis is not fully established. 
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Figure 1.3: Binding partners of Par-4 
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Functional role of Par-4 
Although the exact physiological role of endogenous Par-4 protein is not known, 
several functions are uncovered by the interesting array of molecules that Par-4 affects 
and/or interacts with. All of the partners of Par-4 identified to date are involved with cell 
survival, transformation or apoptosis. Human Par-4 was first identified as a binding 
partner and inhibitor of WT1 and the aPKC (Johnstone et al., 1996) (Diaz-Meco et al., 
1996). Par-4 also binds and enhances the apoptotic function of DAP-like kinase (Dlk/Zip 
kinase) (Kogel et al., 1998) (Fig. 1.3). Par-4 inhibits the pro-survival proteins Bcl-2 and 
NF-κB, and in addition it down regulates the Extracellular Signal-Regulated kinase ERK-
2 expression. It also enhances apoptosis by inducing the translocation of Fas/FasL to the 
cell membrane. 
The Wilms' tumor 1 gene (WT1) encodes a tumor suppressor whose loss is 
associated with the etiology of Wilms' tumor. In fact, it is the only gene known to be 
involved in the development of this tumor. It is homozygously mutated in 5-10% of 
Wilms' tumors (for a recent review see reference (Scharnhorst et al., 2001)). Germ-line 
mutations revealed the essential role of WT1 in normal genitourinary development. 
Differential splicing of the expressed WT1 mRNA results in the expression of a number 
of zinc finger isoforms of the protein. WT1 was thought to either repress or activate 
transcription according to different promoter and cellular contexts. Transcriptional 
repression by WT1 was shown using reporter assays under the control of GC-rich 
promoter. However, no endogenous genes that are inhibited by WT1 under physiological 
conditions have been identified. On the other hand, transcriptional activation by WT1 has 
recently acquired physiological relevance because transactivation by WT1 is implicated 
in cellular differentiation and in repression of proliferation-associated genes by activating 
p21 (Lee and Haber, 2001). 
Par-4 binds to the zinc finger of WT1 via its C-terminal leucine zipper domain. 
This binding results in the inhibition of WT1 activated transcription. In experiments 
designed to understand the biological significance of the Par-4/WT1 interaction, it was 
found that Par-4 inhibits the growth arrest induced by WT1 in melanoma cells, which is 
in agreement with Par-4 function as a pro-apoptotic protein. (Johnstone et al., 1996) 
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(Sells et al., 1997). The relation between Par-4 and WT1 implies a possible involvement 
of Par-4 in the development of some tumors such as Wilms' tumor and human male germ 
cell tumors. Par-4 can bind to a mammalian isoform of WT1 outside the zinc finger 
domain and this complex is involved in transcriptional activation. A mutation in this 
isoform occurs in Wilms tumor, and results in disruption of both the transactivation 
function of WT1 and its binding to Par-4. (Richard et al., 2001). Disruption of the 
binding between WT1 and Par-4 was also found to be associated with desmosplastic 
small round cell tumors (Kim et al., 1998). A better understanding of the physical and 
functional interaction between Par-4 and WT1 is required in order to elucidate their role 
in cancer; such studies may unveil a new target for tumor treatment.  
ζPKC and λ/ιPKC are 72% homologous members of the aPKC subfamily with 
similarities, especially in the catalytic domain to other PKC isoforms belonging to the 
classical and novel subfamilies. aPKCs have only one zinc finger domain and, unlike the 
classical PKC subfamily, they lack the C2 domain, thus being non-responsive to 
activation by Ca2++, diacylglycerol and phorbol esters. Growing evidence suggests that 
aPKCs play an important role in cell growth and survival, presumably through regulation 
of NF-κB and AP-1 pathways; for example, ζPKC is involved in NF-κB activation by 
TNF-α, IL-1, LPS and Ras at multiple levels (Moscat and Diaz-Meco, 2000). 
The leucine zipper domain of Par-4 binds to the zinc finger region of the aPKCs. 
This interaction was discovered in yeast two-hybrid studies and further confirmed by in 
vitro and in vivo assays. Interestingly, the zinc finger region lies within the regulatory 
domain of aPKCs implying a regulatory role for Par-4. Indeed, the enzymatic activity of 
ζPKC is effectively inhibited by Par-4 protein in vitro. As an indication of the 
physiological relevance of the Par-4/aPKC binding, Par-4 was shown to inhibit the 
expression of reporter genes under the control of AP-1. This inhibition was rescued by 
over-expression of λ/ιPKC. The interaction with Par-4 also inhibits the ability of ζPKC 
to activate NF-κB. In addition, cells over-expressing Par-4 and induced to undergo 
apoptosis by withdrawal of serum, were rescued by over-expression of ζPKC (Diaz-
Meco et al., 1996).  
ζPKC seems to fit well with the suggested functions of Par-4. Both ζPKC and 
Par-4 have specific but opposing effects on apoptosis, NF-κB activity and Fas function 
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and both of them are affected by ceramide (Muller et al., 1995) (Bourbon et al., 2002). 
This close relationship tempted some groups to believe that ζPKC is the only mediator of 
Par-4 functions. Recently, the interaction between these two proteins drew further 
attention when it was found that they form a ternary complex with p62 (Chang et al., 
2002). p62 is a zinc finger protein that binds to the SH2 domain of p56lck in a phospho-
tyrosine-independent manner (Joung et al., 1996). p62 was identified as an adaptor 
partner of aPKCs by two separate groups (Sanchez et al., 1998) (Puls et al., 1997). 
Sanchez et al. showed that p62 is not a substrate for aPKCs and it does not regulate their 
kinase function. p62 acts as an adaptor protein that bridges ζPKC to either RIP or TRAF-
6 (Sanz et al., 1999). This relationship explains the ability of ζPKC to phosphorylate 
IKKβ and activate NF-κB in response to TNF-α and IL-1 stimulation. However, the 
discovery of the ternary complex formed between Par-4/p62/ζPKC revealed a more 
active function for p62; it is able to reactivate catalytically inactive ζPKC that is bound to 
Par-4. As a result, over-expression of p62 protects cells from Par-4-mediated inactivation 
of NF-κB and from apoptotic death. 
The binding between aPKCs and p62 was mapped to the V1 region of the 
regulatory domain of the kinases and to a recently identified domain termed AID (for 
Atypical PKC-Interacting Domain) (Moscat and Diaz-Meco, 2000) between amino acids 
66 and 83 of p62. Interestingly, the leucine zipper of Par-4, which binds to ζPKC, is also 
involved in binding to p62 between amino acids 50 and 80 (Chang et al., 2002). More 
precise mapping of the binding sites between these three proteins is needed to clarify the 
complex formation. 
Another partner of Par-4 is DAP-like kinase or ZIP kinase (Dlk/ZIP kinase) 
(Kogel et al., 1998). The kinase domain shows 81% amino acid sequence identity to DAP 
kinase (death associated protein kinase), which is involved in interferon γ-induced cell 
death (Deiss et al., 1995). Dlk/ZIP kinase is one of five members in the DAP kinase 
family. They are all ubiquitously expressed in various tissues and are capable of inducing 
apoptosis upon over-expression in cultured cells. Their apoptotic function depends 
strictly on their enzymatic activity (Kawai et al., 1999) (Kogel et al., 2001a). Dlk 
contains a leucine zipper domain that mediates homo- and hetero-dimerization; therefore 
the mouse homologue was named zipper interacting protein (ZIP) kinase (Kawai et al., 
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1998). Dlk/ZIP kinase is tightly associated with speckle-like nuclear structures, some of 
which overlap with PML bodies. Localization to these nuclear structures and binding to 
the transcription factor ATF4 suggests a role for Dlk/ZIP kinase in transcription control. 
Dlk exhibits auto-phosphorylation and also trans-phosphorylates histones H3 and H4, as 
well as, myosin light chain in vitro (Kogel et al., 1999).  
The interaction between Par-4 and Dlk was first detected in the yeast two-hybrid 
assay and then in GST pull-down experiments. Surprisingly, the leucine zipper domain of 
Dlk is not involved in binding to Par-4. On the other hand, the leucine zipper domain of 
Par-4 and the kinase activity of Dlk are both required for their interaction. Co-expression 
of Dlk and Par-4 leads to relocation of Dlk from the nucleus to the cytoplasm, 
particularly to actin filaments. This re-localization was associated with induction of 
apoptosis. The authors suggest that nuclear Dlk is inactive in the nucleus, and that 
binding to Par-4 and relocation to the cytoplasm activate its apoptotic abilities. Par-4 was 
also found to be phosphorylated by Dlk in vitro, suggesting a more complex relationship 
between these two proteins (Kogel et al., 1998). 
Another interesting relationship was noted between Par-4 and the anti-apoptotic 
protein Bcl-2. In the immortalized mouse fibroblast NIH 3T3 cells and in human prostate 
cancer cells PC3, over-expression of Par-4 resulted in down-regulation in Bcl-2 protein 
levels. When Bcl-2 levels were restored in cells over-expressing Par-4, Bcl-2 was able to 
protect against apoptosis without affecting Par-4 levels. In addition, 
immunohistochemical analysis of a number of primary and metastatic cancer tissue 
samples showed mutually exclusive expression of Bcl-2 or Par-4. Tumor samples 
showing high expression of Par-4 had no Bcl-2. The same pattern was seen in androgen-
dependent human prostate cancer xenograft CWR22 and isogenic androgen-independent 
prostate tumor xenograft CWR22R, where the presence of Par-4 was associated with 
absence of Bcl-2. Some foci showed higher levels Bcl-2 that were accompanied by lower 
Par-4 protein levels. These foci may confer a selective growth advantage that might result 
in an expansion of the Bcl-2-positive compartments within the CWR22R tumor (Qiu et 
al., 1999a).  
Interestingly, the inverse relationship between Par-4 and Bcl-2 may also be valid 
in apoptosis induction associated with nervous system development. In a study examining 
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the involvement of ceramide and ganglioside in mouse brain development, a cell line 
representing the mouse brain at day E16.5 of embryonal development (ST2-FLAG-GFP-
transfected F-11A cells) was used. These cells show low levels of Par-4 protein and high 
levels of Bcl-2 and are relatively resistant to apoptosis. When Par-4 level was restored by 
inhibiting the mitogen activated protein kinase (MAPK) pathway, the level of Bcl-2 
protein decreased (Bieberich et al., 2001).  
Part of the relationship between Par-4 and Bcl-2 protein levels became clear when 
it was found that Par-4 directly inhibits bcl-2 gene expression by binding to its promoter 
via WT1. In response to the vitamin A derivative ATRA (all trans-retinoic acid), Par-4 
translocates to the nucleus in prostate cancer cell lines and the Par-4/WT1 complex binds 
to the bcl-2 promoter and inhibits its expression. As a result of Bcl-2 repression, the 
prostate cancer cells undergo cell arrest and apoptosis (Cheema et al., 2002). 
bcl-2 is a proto-oncogene isolated from human follicular B cell lymphoma 
(Tsujimoto et al., 1984). It is associated with the mitochondrial membrane (Krajewski et 
al., 1993) and is known to promote long-term survival of cells. Bcl-2 over-expression is 
involved in at least two human malignancies, follicular center B cell lymphoma and 
chronic lymphocytic leukemia (Hanada et al., 1993), and correlates with poor prognosis 
in non-Hodgkins lymphoma and the emergence of androgen independent prostatic 
carcinoma. In humans, a point mutation abolishing the growth arrest function of Bcl-2 is 
observed in the transformation of human follicular lymphoma into more aggressive 
disease. Bcl-2 over-expression inhibits apoptosis in vitro in response to a number of 
chemotherapeutic agents. Deregulation of Bcl-2 expression essentially contributes to 
accumulation of oncogenic mutations by suppressing apoptotic deletion of cells following 
the induction of DNA damage. Considering the pro-survival role played by Bcl-2 in 
many tumors, its inhibition is a prime consideration in a number of anti-cancer drugs 
(Huang, 2000). The ability of Par-4 to down-regulate and inhibit Bcl-2 can be used as a 
tool to target cancers resulting from Bcl-2 over-expression. 
Involvement in cancer 
In an attempt to identify the status of Par-4 in cancers, normal and tumor tissues 
from at least 25 patients with pathologically confirmed neuroblastomas, prostate cancers, 
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head and neck tumors, or renal cell carcinomas (RCC) were examined for Par-4 
expression. Only the RCC samples showed reduction in the protein levels of Par-4 
relative to the corresponding normal tissues, as judged by immuno-histochemistry and 
Western blot analysis. When Par-4 levels were restored in RCC cell lines, they showed 
increased sensitivity to apoptosis induction by doxorubicin and TNF-α (Cook et al., 
1999). In a later study involving neuroblastoma cell lines, Par-4 was lost in three out of 
seven cell lines examined (Kogel et al., 2001b). 
Over-expression of Par-4 in mouse melanoma B16 F1 cells decreases their 
migration ability in a ζPKC dependent manner. The mechanism by which the migration 
was affected was not elucidated but in the presence of low levels of ζPKC, Par-4 did not 
affect cell migration (Sanz-Navares et al., 2001).  
Together, these observations imply a possible involvement of Par-4 in cancers. A 
more direct relationship was revealed in mouse fibroblast NIH 3T3 cells, wherein 
different oncogenes such as Ras, Raf or Src were found to reduce Par-4 mRNA and 
protein levels. The effect of Ras was not restricted to NIH 3T3 cells; but it was also found 
in mouse embryonic fibroblast and the human cervical cancer cell line HeLa (Barradas et 
al., 1999). Inhibition of Par-4 by Ras occurs through the Raf-MEK-ERK pathway: 
constitutively active forms of Raf, MEK and ERK decrease the levels of Par-4. More 
interestingly, restoration of Par-4 in mouse fibroblast cells expressing stable or inducible 
oncogenic Ras, decreased ERK protein levels and inhibited cellular transformation as 
measured by the absence of foci in cell culture and impaired colony formation in soft 
agar (Barradas et al., 1999) (Qiu et al., 1999b). In addition, Par-4 directly induced 
apoptosis in oncogenic Ras expressing cells (Nalca et al., 1999). Moreover, NIH 3T3 
cells stably transfected with both Ras and Par-4 (i.e. cells that are resistant to direct 
apoptosis by Par-4) undergo apoptosis when death pathways are induced by TNF-α. In ex 
vivo experiments, the Ras/Par-4 cells were less efficient in developing tumors in nude 
mice and more sensitive to the chemotherapeutic agent camptothecin (Qiu et al., 1999b).  
A more fascinating result emerged from the effect of over-expressing Par-4 in 
androgen independent cell line PC3: these cells underwent direct apoptosis in response to 
Par-4 over-expression. In nude mice, a single injection of Par-4-expressing adenovirus in 
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solid tumors formed by PC3 cells resulted in a remarkable reduction of tumor size 
compared to the tumors injected with the control adenovirus (Chakraborty et al., 2001). 
Involvement in neurodegenerative disorders 
In contrast to the essential role played by apoptosis in neuronal development, the 
adverse effects of apoptosis are obvious in several different neurodegenerative conditions 
like stroke (Linnik et al., 1993), Alzheimers (AD) (Loo et al., 1993), Huntingtons 
(Zeitlin et al., 1995) and Parkinson's disease (Anglade et al., 1997). 
Apoptosis in the adult nervous system has serious implications for the whole 
organism, since the nervous system is not classically known to undergo active 
regeneration. In contrast to the rapid turnover of cells in proliferative tissues, neurons 
commonly survive for the entire lifetime of the organism. Thus, contrary to the beneficial 
elimination of unwanted or rapidly replaceable cells by a rapid caspase cascade, 
apoptosis in the developed brain is detrimental to the host and must be tightly controlled. 
Various signals, such as lack of neurotrophic factor support, over-activation of glutamate 
receptors and increased oxidative stress, can trigger apoptosis in neurons (Mattson, 
2000). Studying the molecular mechanisms controlling neuronal apoptosis is an essential 
requirement for the identification of targets for drugs against neurodegenerative diseases. 
Par-4 can be classified as such a target since it plays a critical role in neuronal apoptosis. 
The expression of endogenous Par-4 is up-regulated in different 
neurodegenerative diseases. A first indication of the involvement of Par-4 in neuronal 
disease was its up-regulation in the AD patients (Guo et al., 1998a). Both Par-4 mRNA 
and protein increase in brain regions that are sensitive to neurodegeneration in AD but 
not in those regions that are resistant. Hippocampal tissues and the inferior parietal cortex 
in AD patients showed 8 to 20 fold increase in the Par-4 protein levels compared to the 
age-matched control. Cell culture studies using primary rat hippocampal neurons 
demonstrated that Par-4 levels increase in response to staurosporine or neuron-specific 
apoptotic insults such as amyloid β-peptide (Aβ1-42). Moreover, Par-4 was able to 
sensitize PC12 cells and primary hippocampal neurons to apoptosis following trophic 
factor withdrawal, Aβ1-42 and exposure to oxidative insults. Interestingly, the ability of 
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these agents to induce apoptosis is dependent on Par-4 because an antisense 
oligodeoxynucleotide of Par-4 abrogates apoptosis. 
It is widely accepted that neuronal degeneration in AD is caused by extracellular 
accumulation of Aβ142. Mutations in familial Alzheimers disease genes, such as β-
amyloid precursor protein (βAPP), presenilin-1, and presenilin-2, affect the processing of 
β-amyloid precursor protein (βAPP) and result in increased production of the longer form 
of Aβ142 (Selkoe, 1996). In addition, these genes have been shown to regulate neuronal 
apoptosis, suggesting that disruption of apoptotic pathways may play an important role in 
neuronal degeneration in AD. Abnormal processing of βAPP and increased production of 
Aβ may be induced by apoptotic insults (Guo et al., 2001a). 
Par-4 involvement in sensitization of neurons to apoptosis was noted as an early 
event. The use of Par-4 antisense oligodeoxynucleotide inhibited the production of 
mitochondrial reactive oxygen species and depolarization of the mitochondrial membrane 
that are involved in induction of apoptosis by Aβ1-42. In addition, inhibition of Par-4 
decreased caspase 3 activation. Par-4 involvement in early events of neuronal apoptosis 
was evident from immunohistochemical analysis; 30-50% of the hyperphosphorylated 
Tau-positive cells co-expressed Par-4. The absence of Par-4 in the remaining cells 
positive for Tau maybe because Par-4 levels increased early in the apoptotic process then 
disappeared, while Tau persisted much longer. 
Interestingly, secretion of Aβ142 increased after trophic factor withdrawal in a 
human neuroblastoma IMR-32 cell line, which stably over-expressed ectopic Par-4. It is 
suggested that the mechanism by which Par-4 increases Aβ142 secretion involves 
interaction of Par-4 with other proteins via the leucine zipper domain. In addition, Par-4-
induced secretion of Aβ142 was caspase-dependent and occurred when apoptotic 
cascades were initiated (Guo et al., 2001a). Recently, Xie et al. showed that when 
hippocampal neurons derived from presenilin-1 M146V mutant knock-in mice were 
subjected to glucose deprivation, endogenous Par-4 expression was rapidly and 
significantly increased. These cells were almost completely rescued from apoptosis 
induced by glucose deprivation when treated with Par-4 antisense oligodeoxynucleotide 
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(Xie et al., 2001). These observations strongly suggest that induction of Par-4 is an 
important and necessary event in the pathogenic mechanisms of AD. 
The critical role of Par-4 in the nervous system has gained increasing support over 
the years. Par-4 levels increase rapidly in the synaptosomes in response to oxidative and 
apoptotic insults. This increase occurs at the protein level. Loss of mitochondrial 
membrane potential and decrease in respiratory chain reaction, as well as caspase 
activation, were largely inhibited when the Par-4 antisense oligodeoxynucleotide was 
used (Duan et al., 1999). Par-4 levels were elevated in human hippocampal neurons of 
HIV patients and in monkeys infected with a chimeric strain of HIV-1 and simian 
immunodeficiency virus (Kruman et al., 1999). Cultured hippocampal neurons showed an 
increase in endogenous Par-4 after exposure to the neurotoxic HIV-1 protein Tat, and 
treatment of the cultures with a Par-4 antisense oligonucleotide protected the neurons 
against Tat-induced oxidative stress, mitochondrial dysfunction, caspase activation and 
apoptosis. Tat is one of several proteins expressed by the human immunodeficiency virus 
type-1 (HIV-1) that are essential for viral replication and have neurotoxic effects (Nath 
and Geiger, 1998) (Dayton et al., 1986). Tat can interact directly with the neuronal 
plasma membrane and induce apoptosis of primary human and rodent cortical neurons by 
a mechanism involving calcium influx and mitochondrial dysfunction (Kruman et al., 
1998). Subsequent studies noted Par-4 elevation in response to numerous apoptotic 
insults in neurons. Cultured embryonic rat hippocampal neurons subjected to trophic 
factor withdrawal, showed rapid increase in Par-4 mRNA and protein levels that was 
downstream of oxidative stress and membrane lipid peroxidation but upstream of 
mitochondrial dysfunction, caspase activation and cell death. The increase was attenuated 
by antioxidants and estrogen (Chan et al., 1999).  
In Parkinson's disease models, administration of 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) to monkeys and mice dramatically increased Par-4 levels in 
the substantia nigra (SN). The increase preceded the mitochondrial dysfunction and cell 
death, and both were inhibited in human neuroblastoma dopaminergic cell line (SK-N-
MC) when pretreated with Par-4 antisense oligodeoxynucleotide (Duan et al., 1999). 
Lumbar spinal cord samples from patients with amyotrophic lateral sclerosis 
(ALS) showed higher Par-4 levels than lumbar spinal cord samples from neurologically 
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normal patients. Par-4 was also higher in lumbar spinal cord samples from ALS 
transgenic mice, expressing the human Cu/Zn-superoxide dismutase gene with a familial 
ALS mutation, when compared to wild type mice. Immunohistochemical analyses of 
human and mouse lumbar spinal cord sections revealed that Par-4 is localized to motor 
neurons in the ventral horn region. Primary mouse spinal cord motor neurons or NSC-19 
motor neuron cells were rescued from apoptosis induced by oxidative insults when 
pretreated with Par-4 antisense oligonucleotide (Pedersen et al., 2000).  
The same pattern of Par-4 up-regulation was noted in animal and cell culture 
models of ischemic brain injury or stroke. Par-4 levels increased in vulnerable 
populations of hippocampal and striatal neurons in rats after transient forebrain ischemia 
and in infarcted cortex and the striatum of mice after transient focal ischemia. Activation 
of caspase-8 occurred with a similar time course as Par-4 elevation. In tissue culture 
models, where ischemia is induced by chemical hypoxia, the antisense oligonucleotide of 
Par-4 protected the cultured hippocampal neurons from apoptosis. In addition, Par-4 
antisense oligonucleotide injected into the right ventricle of mice through intraventricular 
infusion significantly reduced focal ischemic damage after transient middle cerebral 
artery occlusion (Culmsee et al., 2001). 
Par-4 was also found to play a similar role in the Huntingtons disease rat models 
induced by systemic administration of the succinate dehydrogenase inhibitor 3-
nitropropionic acid (3NP) (Duan et al., 2000). Huntingtons disease is an inherited fatal 
neurodegenerative disorder (Reiner et al., 1988). Caspase activation and apoptosis, but 
not Par-4 up-regulation, were inhibited in tissue culture models using caspase inhibitors. 
The inability to inhibit up-regulation of Par-4 prior to apoptosis induction with caspases 
inhibitors suggests that Par-4 acts upstream of caspases activation.  
Despite the clear involvement of Par-4 in neuronal cell death, its physiological 
function in neuronal tissues is still not clear. Recently, it was suggested that Par-4 may 
play a synaptic function. Par-4 was found to preferentially localize in synaptosomes, 
which represent isolated nerve terminals that form synaptic contacts among neurons. A 
more refined localization placed Par-4 in the postsynaptic compartment of the 
synaptosome called the postsynaptic density (PSD). PSD is a disc-shaped proteinaceous 
structure attached to the inner surface of the postsynaptic membrane of dendrites and 
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spines. It is believed to be central to synaptic functions of the mammalian central nervous 
system since it contains cytoskeletal proteins, cytoskeleton-associated molecules and 
molecules that are required for the signal processing, such as postsynaptic receptors and 
kinases (for example, calcium/ calmodulin-dependent protein kinase II, CaMKII).  This 
makes the PSD a major site for modulation of neuronal signal transduction. The 
expression of Par-4 in synaptosome preparations and PSDs is developmentally and 
regionally regulated. Synaptic Par-4 is enriched in the cerebral cortex and the 
hippocampus, but not in the cerebellum. In vitro as well as in vivo experiments 
demonstrated that the levels of synaptic Par-4 increased as the neurons matured. In 
cultured hippocampal neurons from postnatal day 1-mouse pups, there was a sharp and 
pronounced increase in Par-4 immuno-reactivity in the dendrites compared to a relatively 
moderate increase in Par-4 immuno-reactivity in the cell body as neurons mature. In 
PC12 cells, over-expression of Par-4 inhibited neurite outgrowth in response to nerve 
growth factor (NGF). Par-4 might inhibit neurite outgrowth by aberrantly increasing 
intracellular calcium concentration in response to NGF to a level significantly higher than 
optimal for neurite outgrowth and by inhibiting activation of the transcription factor AP-
1, which is involved in NGF-induced differentiation of PC12. Identification of Par-4 as a 
novel synaptic protein may have significant implications in understanding the 
mechanisms of synaptic functions in physiological and pathological settings (Guo et al., 
2001b). 
In addition to the importance of Par-4 in neurodegenerative diseases and in 
synapses, a recent report suggested a role for Par-4 in mouse nervous system 
development. This study analyzed lipid and protein composition of the mouse brain 
during the gestational days E12 and E18 when about half of the proliferative neurons and 
glial cells die by apoptosis (Blaschke et al., 1996). The findings suggested that 
gangliosides act as potential anti-apoptotic effectors during early mouse brain 
development. In tissue culture models, an increase in b-series complex gangliosides was 
accompanied by a decrease in Par-4 and ceramide-induced apoptosis and by an increase 
in Bcl-2. Inhibition of ganglioside formation reversed Par-4 and Bcl-2 patterns restoring 
the normal endogenous levels of both proteins (Bieberich et al., 2001). 
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Mechanism of apoptosis by Par-4 
The pro-apoptotic role of Par-4 is apparent from its effect when over-expressed in 
different cell lines, its effects in cancer and neurodegenerative disease paradigm and from 
the interesting array of its partner proteins. Consistently, multiple mechanisms are 
involved in its ability to induce apoptosis (Fig. 1.4).  
Interaction with WT1 may be involved in inhibition of growth arrest and 
inhibition of Bcl-2, which is a potent anti apoptotic protein (Johnstone et al., 1996) 
(Cheema et al., 2002) (Qiu et al., 1999a). Down-regulation of Bcl-2 allows apoptotic 
signals to proceed without its protective intervention. On the other hand, the binding of 
Par-4 to DLK enhances its apoptotic abilities by a mechanism that is yet to be revealed. 
Par-4 is able to down-regulate the expression of mitogen activated protein (MAP) 
kinases ERK1 and ERK2 in NIH 3T3 mouse fibroblast cells in a Ras dependent manner 
(Qiu et al., 1999b). ERK1/2 couples several cell surface stimuli to cellular functions, they 
act as inducers of proliferation in response to growth factor stimulation, and mediate 
cellular transformation (Leevers and Marshall, 1992). Down-regulation of ERK may be 
one of the mechanisms by which Par-4 facilitates the induction of apoptosis and/or 
interferes with Ras induced transformation. 
Of the activities of Par-4, those that are the most studied and better linked to 
apoptosis are its ability to inhibit NF-κB dependent transcription activation; its inhibitory 
effects on the function of ζPKC; and its ability to increase Fas and FasL translocation and 
activation. Two reports revealed that Par-4 inhibits NF-κB activity in mouse fibroblast 
cells. NF-κB is a transcription factor that was discovered in mature B cells (Sen and 
Baltimore, 1986) (NF-κB is discussed in more details in the introduction of Chapter 3). It 
is a member of a large family of transcription factors formed by hetero- or homo-
dimerization between members of the Rel family. The most prominent form of NF-κB is 
a heterodimer between the subunits p65 (RelA) and p50. NF-κB is present in an inactive 
form bound to the inhibitor protein IκB in the cytoplasm. In response to various stimuli, 
NF-κB can be activated at two different levels. The first involves IκB phosphorylation by 
IKKβ (or other kinases) and its subsequent degradation resulting in the release of NF-κB. 
The latter is then free to translocate to the nucleus, where it binds to specific sequences in 
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the DNA and activates the transcription of specific genes (Baldwin, 1996). The second 
level of activation involves changes, such as phosphorylation by ζPKC (Anrather et al., 
1999) or IKK (Sakurai et al., 1999) in the RelA subunit that enhances its transcriptional 
activity. NF-κB plays a crucial role in inflammation and immune response by activating 
the transcription of a number of key cytokines and cytokine receptors (Barnes and Karin, 
1997). In addition to its role in the immune system NF-κB has an important regulatory 
role in apoptosis (Barkett and Gilmore, 1999) and cell proliferation (Perkins, 2000). It 
antagonizes apoptosis by enhancing the expression of some anti-apoptotic proteins like 
Inhibitor of Apoptosis Proteins (IAPs) and affects proliferation by increasing the 
transcription of genes like c-myc and cyclin D1. It is now well accepted that NF-κB plays 
an important role in oncogenesis and in resistance of tumor cells to chemotherapy (Rayet 
and Gelinas, 1999). NF-κB is also required by some oncogenes, such as Ras, for 
accomplishing transformation (Finco et al., 1997) (Perkins, 2000). 
We found that Par-4 was able to inhibit the Ras- or Raf-induced transcriptional 
activity of NF-κB. Ras or Raf increased this activity without affecting IκB degradation or 
NF-κB nuclear translocation and DNA binding. The effect of Par-4 localized at the 
transactivation domain (TA1) of the RelA subunit of NF-κB. Interestingly, in NIH 3T3 
cells with inducible Ras, inhibition of NF-κB activity by super-repressor IκBα, was 
sufficient to induce apoptosis (Mayo et al., 1997). As expected, over-expression of Par-4 
is, by itself, sufficient to induce apoptosis in these cells (Nalca et al., 1999). 
Diaz-Meco et al. reported that Par-4 inhibited TNF-α induced NF-κB activity, 
thus enhancing the apoptosis pathway initiated by TNF-α. In this study, Par-4 was able to 
inhibit IκB phosphorylation and subsequent NF-κB nuclear translocation induced by 
TNF-α treatment. They further showed that Par-4 accomplished this action by inhibition 
of IKKβ activation in response to TNF-α, thereby interfering with IκB phosphorylation. 
Furthermore, over-expression of a constitutively active λ/ιPKC restored IKKβ activity 
and lead to phosphorylation of IκB. These findings suggest that binding and inhibition of 
aPKC by Par-4 is responsible for inhibition of TNF-α induced NF-κB activation (Diaz-
Meco et al., 1999). Because Par-4 inhibits RelA transcriptional activity induced by Ras 
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and also inhibits TNF-α induced NF-κB translocation, we suggest that Par-4 inhibits NF-
κB activity at both levels of its activation. 
Another recently identified function of Par-4 is its ability to translocate Fas and 
Fas ligand to the plasma membrane (Chakraborty et al., 2001). Fas (CD95) is a member 
of the TNF-R family of death receptors. It is activated by binding to Fas ligand in 
solution or on the cell surface leading to the formation of an aggregate called the death 
inducing signaling complex (DISC) (Kischkel et al., 1995). The DISC is composed of the 
trimerized Fas, the Fas associated death domain (FADD) protein and pro-caspase 8, and 
its formation leads to the activation of caspase 8 and further to induction of downstream 
caspases and apoptosis (Peter and Krammer, 1998).  
Par-4 is able to translocate Fas and FasL to the membrane in androgen-
independent prostate cancer cell lines (e.g. PC3 and DU145) as part of the mechanism by 
which it induces apoptosis in these cells. Par-4 over-expression can directly kill these 
cells without the need of another insult such as growth factor withdrawal, TNF-α 
treatment or oncogenic Ras over-expression. Direct induction of apoptosis by Par-4 
requires both Fas/FasL translocation and NF-κB inhibition. Fas and FasL translocation 
was also detected in tumors that shrunk in response to Par-4 treatment in nude mice. On 
the other hand, androgen-dependent prostate cancer cell lines (e.g. LNCaP) are resistant 
to Fas/FasL translocation and to direct apoptosis by Par-4.  
The mechanism by which Par-4 translocates Fas/FasL to the membrane is not 
known, but it is interesting to note that Par-4 also affects another part of Fas induced 
apoptotic pathway. Leukemic CD34+ immature acute myeloid leukemia (AML) cells 
express Fas but are usually resistant to Fas induced apoptosis. de Thonel et. al showed 
that this resistance arises from a defect in DISC resulting from the phosphorylation of 
FADD by ζPKC (de Thonel et al., 2001). Interestingly, the phosphorylation of FADD 
can be inhibited by Par-4 over-expression. This finding suggests that Par-4 can enhance 
Fas induced apoptosis by increasing its membrane translocation and also by rescuing it 
from the anti-apoptotic effects of ζPKC. 
The Par-4/ζPKC relationship can explain some aspects of the mechanism of 
induction of apoptosis by Par-4. As discussed earlier, ζPKC has an important role in cell 
proliferation and survival: it may mediate part of the effect of Par-4 on NF-κB activity; it
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Figure 1.4: Current model of the mechanism of action of Par-4. Par-4 affects multiple 
pathways regulating cell survival both in the cytoplasm and in the nucleus. In the 
cytoplasm, Par-4 increases Fas and FasL translocation to the membrane. Moreover, it 
binds and inhibits ζPKC functions such as activation of IKKβ and inhibition of Fas 
signaling. In the nucleus, Par-4 inhibits NF-κB transcriptional activity by mechanisms 
that may in part involve ζPKC. In addition, Par-4 inhibits expression of the Bcl-2 
promoter by interacting with WT1.  
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Figure 1.4: Current model of the mechanism of action of Par-4. 
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has a role in inhibition of the Fas pathway, which Par-4 can counteract; and inhibition of 
ζPKC by Par-4 results in activation of the MAPK p38, which has been implicated in 
induction of apoptosis in epithelial and fibroblast cells (Berra et al., 1997). 
Similar mechanisms may be involved in induction of apoptosis by Par-4 in 
neuronal cells. Studies in neurons identified Par-4 action as an early event in the 
apoptosis cascade. It was positioned upstream of mitochondrial involvement and caspase 
activation (Kruman et al., 1999). A more detailed analysis of the function of Par-4 in 
neurons, localized it in a critical position to affect neuronal signaling. It was found to 
localize in the PSD. Over-expression of Par-4 in PC12 cells increases levels of 
intracellular calcium, which may be involved in apoptosis induction. In addition, as was 
found in other types of cells, Par-4 over-expression inhibits activation of NF-κB and AP-
1 and down-regulates Bcl-2 expression in PC12 cells (Guo et al., 2001b) (Camandola and 
Mattson, 2000). The implications of the ability of Par-4 to inhibit NF-κB can be best 
appreciated when one considers the importance of this transcription factor in neurons. 
NF-κB is activated in many cells in response to potentially lethal stress factors, such as 
exposure to oxidative insults, TNF-α, and agents that elevate intracellular calcium levels 
(Mattson, 2000) (Baeuerle and Baltimore, 1996), and activation of NF-κB can protect 
primary neurons and PC12 cells against apoptosis (Barger et al., 1995) (Mattson et al., 
1997) (Taglialatela et al., 1997) (Guo et al., 1998b). The gene targets responsible for the 
anti-apoptotic action of NF-κB may include antioxidant enzymes (Mattson et al., 1997), 
proteins of the IAP family (Deveraux and Reed, 1999), and Bcl-2 family members 
(Tamatani et al., 1999).  
Potential for Par-4 in molecular therapeutics 
Gene therapy has been used to induce apoptotic programs with various degrees of 
success. The first approach was directed to restore normal p53 functions in cancer cells. 
Although the initial results have been interesting, refinement of the vectors and delivery 
concepts is needed. Phase I clinical and pharmacokinetic studies with Bcl-2 antisense 
oligonucleotide (which effectively degrades messenger RNA) in patients with non 
Hodgkin's lymphoma was well tolerated. Bcl-2 protein level was reduced in 44% of the 
patients. Out of 21 patients 3 showed some response to the treatment (Waters et al., 
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2000). Other experimental gene therapy protocols in the clinic point to the feasibility of 
these types of therapies. However, it is likely they will be more efficient when combined 
with chemotherapy, radiation or even anti-angiogenesis treatments, all of which trigger 
apoptosis (Sjostrom and Bergh, 2001). 
Through the years, evidence in favor of Par-4 as a candidate for gene therapy has 
been accumulating. Its ability to inhibit transformation in Ras expressing cells was a 
major step in this direction (Nalca et al., 1999). This was followed by the mouse 
experiments wherein a single injection of an adenovirus expressing Par-4 resulted in an 
amazing regression in solid tumors arising from PC3 cell implants in nude mice 
(Chakraborty et al., 2001) and in RM-1 cell derived orthotopic prostatic tumors in 
immunocompetent mice (Herman et al.). 
In human cells, the potential for Par-4 in the treatment of cancers was suggested 
by the effect of cyclooxygenase (COX) inhibitors on colon carcinoma cells. Non steroidal 
anti-inflammatory drugs (NSAIDs) are emerging as prominent antineoplastic agents (for 
recent reviews see (Kalgutkar and Zhao, 2001)), but the molecular mechanism(s) by 
which NSAIDs inhibit tumor growth are not clear (Thun et al., 1991). Using the 
technique of differential display PCR amplification to compare the gene expression in 
colon carcinoma cells, Par-4 was found to be up-regulated by different COX inhibitors 
(sulindac sulfide and the selective COX-2 inhibitors NS-398, SC-58125 and nimesulide) 
when given at suprapharmacologic concentrations (Zhang and DuBois, 2000). The 
ability of COX-2 inhibitors to induce Par-4 raises the question of whether Par-4 is 
induced as a direct consequence of COX-2 inhibition, thereby suggesting COX-2 inhibit 
endogenous Par-4 expression, or whether the induction results from the action of COX-2 
inhibitors on other cell survival pathways. The role of Par-4 in colon cancer was further 
emphasized when it was found to be up-regulated in HT-29 in response to the apoptosis-
inducing agent polyethylene glycol (PEG). Recent data from experimental models of 
colon cancer suggests that PEG may be the most effective chemopreventive agent studied 
to date, surpassing even the non-steroidal anti-inflammatory drugs (NSAIDs) (Corpet et 
al., 2000). PEG was found to result in a 17-fold induction in Par-4 expression, a finding 
suggesting a potential mechanism for PEG-mediated apoptosis and chemoprevention 
(Roy et al., 2001). Since Ras is frequently activated in colon carcinogenesis (Chung, 
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2000), Par-4 may act at least partly through inhibition of NF-κB and ERK-2. 
Additionally, aPKC isoforms have been previously shown to provide an important 
mechanism in the chemoprevention of colon cancer by NSAIDs (Roy et al., 1995) 
suggesting that the role of Par-4 in chemoprevention of colon cancer may also be through 
inhibition of aPKC. 
The observations so far suggest that Par-4 plays a role in enhancing apoptosis in 
cancers in response to treatment. In addition, animal studies performed by our group, are 
encouraging as tumor reduction was more than expected considering the efficiency of 
transduction of adenoviral Par-4, suggesting a possible bystander effect that may be 
partly explained by the ability of Par-4 to cause Fas/FasL translocation. Importantly, the 
ability of Par-4 to specifically kill cancer cells and spare normal cells makes it an 
attractive choice for metastatic tumor treatment. Par-4, which is a killer of androgen-
independent prostate cancer cells, can be used in combination with hormonal ablation 
therapy as treatment for early prostate cancer in the hope of eliminating recurrence by 
androgen-independent tumors. Further studies are essential to explore different possible 
modes of Par-4 delivery and to study any side effects in normal cells and the whole 
organism. Since a single mode of therapy may not constitute a magic bullet against 
cancer, it is important to study the therapeutic effects of Par-4 in combination with 
chemotherapy or radiotherapy. On the other hand, considering the central role of Par-4 in 
neurodegenerative diseases, therapeutic strategies to specifically target and inhibit the 
apoptotic functions of Par-4 should decrease neuronal cell death that contributes to the 
disease. Because Par-4 induces apoptosis in both cancer and neuronal disease situations, 
the possibility of using Par-4 for cancer therapy may seem to put the normal neurons in 
the cancer patients at an unreasonable risk of apoptosis. However, our finding that Par-4 
does not induce direct apoptosis in normal cells should extend to the normal neuronal 
cells. This speculation needs to be verified by rigorous experimentation in normal 
neurons from various compartments that are likely to be affected during the neuronal 
diseases in which Par-4 elevation in conjunction with other disease-specific 
genotypic/phenotypic alterations potentiates the neuronal apoptosis process. Finally, A 
better understanding of Par-4 regulation mechanisms will allow a better control of its 
functions both in cancer and neuronal cells. 
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Objectives of this work 
To determine the relevance of nuclear localization of Par-4: 
Various observations over the years have pointed to a nuclear role for Par-4 (see 
pages 10, 12). My aim in this work was to determine whether Par-4 translocates to the 
nucleus, to examine the function(s) of nuclear Par-4 and to identify the sequence 
responsible for nuclear localization. The first aim was achieved by using indirect 
immunofluorescence analysis and by transfection of cells with GFP-Par-4 fusion protein. 
I used deletion analysis to identify the nuclear localization sequence and to link nuclear 
entry to NF-κB transcriptional inhibition and the apoptotic function of Par-4.  
To identify the minimal domain of Par-4 essential for apoptosis: 
Rat Par-4 is a 332 amino acid protein (Fig. 1.2) with a number of interesting 
putative domain (see page 7-11 and Table 1.1). My aim in this part of the work was to 
identify which domains of Par-4 are relevant to apoptosis and if the different functions of 
Par-4 are performed by different domains. Finally I wanted to identify the minimum 
sequence of Par-4 needed to induce apoptosis. This domain was identified by performing 
N- and C-terminal deletions of Par-4 followed by functional studies. The core domain 
identified has a wider range of action than full length Par-4, but preserved the apoptotic 
selectivity for cancer cells. This was unexpected but exciting because it suggests a 
possible use in cancer therapy. 
To understand the mechanism of inhibition of NF-kB transcription function: 
The ability Par-4 to inhibit NF-κB is essential for inducing apoptosis 
(Chakraborty et al., 2001). Inhibition of NF-κB by Par-4 is accomplished through 
multiple levels: Par-4 inhibits IκB phosphorylation (Diaz-Meco et al., 1999) and inhibits 
RelA activation. My deletion analysis studies suggested that the current mechanism of 
inhibition mediated by ζPKC does not explain the ability of Par-4 mutants to inhibit NF-
κB or the RelA activation. My final aim was to identify the mechanism by which Par-4 
inhibits RelA transcription activity. Although I was not able to reach a conclusive answer 
to this question, I was able to get a better understanding of the system. Par-4 is able to 
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inhibit various pathways activating RelA. Further analysis is required to determine how 
Par-4 is able to inhibit multiple pathways. On the other hand, this study identified a new 
site of action for the kinases ERK, RSK and ζPKC.  
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CHAPTER 2 
STRUCTURE AND FUNCTION ANALYSIS OF PAR-4 
Introduction 
Par-4 was first isolated from prostate cancer cells undergoing apoptosis (Sells et 
al., 1994). The role of Par-4 as a pro-apoptotic protein was confirmed repeatedly in 
multiple cancer settings and in neurodegenerative diseases. Par-4 is able to directly 
induce apoptosis in androgen-independent prostate cancer cell lines (PC3, DU145) and in 
Ras transformed mouse fibroblasts but not in androgen-dependent prostate cancer 
(LNCaP) and normal cell lines (Chakraborty et al., 2001) (Nalca et al., 1999). In addition, 
over-expression of Par-4 in resistant cell lines renders them sensitive to apoptotic insults 
(Sells et al., 1997). In the nervous system, Par-4 is involved in different diseases like 
Alzheimer's, stroke, ALS, Parkinson's and Huntington's diseases (Guo et al., 1998a) 
(Duan et al., 1999) (Pedersen et al., 2000) (Culmsee et al., 2001) (Duan et al., 2000). Par-
4 levels were elevated in patient samples or in tissue culture models of these diseases. 
Inhibition of Par-4 using a dominant negative mutant or an anti-sense 
oligodeoxynucleotides protected neuronal cells from apoptosis in experimental 
neurodegenerative disease models or in vivo (reviewed in pages 24-30).  
NF-κB plays a crucial role in inflammation and immune response by activating 
the transcription of a number of key cytokines and cytokine receptors (Kischkel et al., 
1995). In addition to its role in the immune system NF-κB has an important role in 
antagonizing apoptosis (Barkett and Gilmore, 1999) and in affecting cell proliferation. It 
is now well accepted that NF-κB plays an important role in oncogenesis and in the 
resistance of tumor cells to chemotherapy (Rayet and Gelinas, 1999). NF-κB is a 
heterodimer between subunits p65 (RelA) and p50. Translocation to the nucleus and 
activation of RelA are required for the full activation of the transcription factor. 
Par-4 inhibits NF-κB activity in mouse fibroblast cells and androgen independent 
prostate cancer cell lines. We found out that Par-4 was able to inhibit the Ras or Raf 
induced transcriptional activity of NF-κB. Ras or Raf increased this activity without 
affecting IκB degradation or NF-κB nuclear translocation and DNA binding. The effect 
 37
 
of Par-4 was found to be localized on the transactivation domain (TA1) of the RelA 
subunit of NF-κB. Interestingly, in NIH 3T3 cells with inducible Ras, inhibition of NF-
κB activity by super-repressor IκBα, was sufficient to induce apoptosis (Mayo et al., 
1997). As expected, over-expression of Par-4 is sufficient to induce apoptosis in these 
cells (Nalca et al., 1999). 
Diaz-Meco et al. reported that Par-4 inhibited TNF-α induced NF-κB activity, 
thus enhancing the apoptosis pathway initiated by TNF-α. In this study, Par-4 was able to 
inhibit IκB phosphorylation and subsequent NF-κB nuclear translocation induced by 
TNF-α treatment. They suggested that binding and inhibition of aPKC by Par-4 is 
responsible for inhibition of TNF-α induced NF-κB activation (Diaz-Meco et al., 1999). 
Because Par-4 inhibits RelA transcriptional activity induced by Ras and also inhibits 
TNF-α induced NF-κB translocation, we suggest that Par-4 inhibits NF-κB activity at 
both levels of its activation (translocation to the nucleus and transactivation of the RelA 
subunit). 
Fas (CD95) is a member of the TNF-R family of death receptors. It is activated by 
binding to FasL in solution or on the surface of another cell leading to the formation of an 
aggregate called the DISC (Kischkel et al., 1995). This complex is composed of the 
trimerized Fas, FADD and procaspase 8. The formation of the complex leads to the 
activation of caspase 8 and to induction of downstream caspases and apoptosis (Peter and 
Krammer, 1998). Par-4 has been shown to affect the Fas pathway by affecting regulation 
of Fas/FasL and by protecting the Fas apoptotic pathway from the inhibitory effects of 
ζPKC (Chakraborty et al., 2001) (de Thonel et al., 2001). Regulation of the Fas pathway 
and inhibition of NF-κB activity are both required for apoptosis induction by Par-4 in 
androgen-independent prostate cancer cell lines (Chakraborty et al., 2001). In the 
following study, I'll be using these two criteria and the ability to induce apoptosis in the 
evaluation of functional Par-4 mutants. 
Despite the advances made in understanding the mechanism of action of Par-4, to 
date, the active domain(s) of Par-4 as well as its functional localization are largely 
unknown. Structure analysis of the 332 amino acid rat Par-4 protein reveals the presence 
of a number of interesting domains. The best studied is the leucine zipper domain at its 
 38
 
C-terminal end (Sells et al., 1997) (Dutta et al., 2001). It is situated between amino acids 
292and 332. It is involved in binding to all known partners of Par-4: WT1 (Johnstone et 
al., 1996), ζPKC (Diaz-Meco et al., 1996), p62 (Chang et al., 2002) and Dlk (Page et al., 
1999). Although Dlk has a leucine zipper domain, it is not involved in binding to that of 
Par-4. The leucine zipper domain is required for sensitization to apoptosis by Par-4. A 
deletion mutant of Par-4 lacking the leucine zipper domain (∆Zip) is unable to sensitize 
melanoma to apoptotic stimuli (Johnstone et al., 1996). Moreover, PC12 cells expressing 
∆Zip are insensitive to Aβ1-42 or withdrawal of trophic factors (Guo et al., 1998a). As a 
result, it was earlier suggested that the C-terminus leucine zipper domain and a putative 
death domain are indispensable for the pro-apoptotic function of Par-4 (Diaz-Meco et al., 
1996). My analysis of Par-4 sequence and function shed more than some doubts on the 
authenticity of the putative death domain. In this work I discovered that the leucine 
zipper domain is not required for direct induction of apoptosis by Par-4. It function seems 
to be more related to binding, localization and maybe inhibition of Par-4. 
Par-4 localization has been a confusing subject. Sequence analysis reveals the 
presence of two putative nuclear localization sequences (Fig. 1.2 and 2.4 A) in the N-
terminal half of Par-4, 108 amino acids apart. At first glance, Par-4 seems to be localized 
in the cytoplasm. In PC12 cells active Par-4 seemed to be localized in the cytoplasm 
(Guo et al., 1998a). No translocation of Par-4 was detected in NIH 3T3 mouse fibroblast 
cells, and removal of the NLS1 by deletion of the first 68 amino acids did not affect the 
function of Par-4 (Diaz-Meco et al., 1999). On the other hand, the presence of a bipartite 
nuclear localization sequence (NLS2), the ability of Par-4 to inhibit RelA activity, 
binding to Dlk, WT1 and inhibit bcl-2 promoter all support the notion of a nuclear 
function for Par-4. 
In this study I will show that NLS1 is not a functional nuclear localization 
sequence and that The N-terminus half of Par-4 maybe be involved in some 
inhibitory/regulatory control of Par-4. The NLS2 is a functional nuclear localization 
sequence required for nuclear entry, inhibition of RelA and induction of apoptosis. Par-4 
is localized both in the cytoplasm and in the nucleus in cells sensitive to direct apoptosis 
induction by Par-4. Cytoplasmic Par-4 is sufficient to affect Fas regulation. In addition, I 
found that the leucine zipper domain is not required for direct induction of apoptosis by 
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Par-4 and that a central core of 67 amino acids that includes NLS2 is sufficient to induce 
apoptosis, RelA inhibition and Fas activation. Amazingly, this minimum functional 
region of Par-4 encodes an extended range of action: it is able to induce apoptosis in the 
cancer cell line resistant to full length Par-4, such as LNCaP but not normal cells. Such a 
small mutant with anti-cancer ability can have important applications in cancer therapy. 
 
MATERIALS AND METHODS: 
1-plasmids: 
pCB6+ (a derivative of pCB6 (Gashler et al., 1993)), pCB6+-Par-4, pCB6+-∆zip 
and 163 (known earlier as Par-4-∆CTH) were described previously (Sells et al., 1997) 
(Johnstone et al., 1996), κB-Luc from CLONTECH Corp. (Palo Alto, CA), pSVβgal (gift 
from Dr. Brett Spear, University of Kentucky), 3x κB-CAT, The Gal4 luciferase (Gal4-
Luc) constructs contain four Gal4 DNA consensus binding sites derived from the 
Saccharomyces cerevisiae located upstream of luciferase reporter gene, and Gal4-RelA 
constructs have the yeast Gal4 DNA binding domain fused to the transactivation domain 
(TA1) of RelA both from Dr. A. Baldwin (University of North Carolina at Chapel Hill, 
Chapel Hill, NC). The GFP cloning plasmids pcDNA3.1/CT-GFP-TOPO and 
pcDNA3.1/NT-GFP-TOPO were from Invitrogen life technologies.  
2-Antibodies and chemical reagents: 
Polyclonal antibodies for Par-4, NF-κB (p65) and Fas were from Santa Cruz 
Biotechnology, Inc. Anti-GFP Rabbit polyclonal from Torrey Pine Biolabs. TUNEL 
enzyme and label from Roche. Propidium iodide from Clonetech. Sepharose G protein 
and GFX PCR DNA and gel band purification kit from Amersham Pharmacia biotech. 
PFU Turbo DNA polymerase and the corresponding buffer from Stratagene. Taq 
polymerase, 10X PCR reaction buffer and 10X PCRx Enhancer solution from Invitrogen. 
DH5α competent cells from Invitrogen. GFP fusion TOPO TA expression kit from 
Invitrogen that includes: pcDNA3.1/CT-GFP-TOPO or pcDNA3.1/NT-GFP-TOPO, salt 
solution (1.2 M NaCl + 0.06 MgCl2), One shot kit TOP10 chemically competent, SOC 
medium and sequencing primers. 
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3-Cell  lines: 
PC3 are maintained in RPMI 1640 with 10% FBS and 1% 
penicillin/streptomycin. LNCaP and LNCaP IGFBP5 are maintained in RPMI 1640 with 
10% FBS, 1% penicillin/streptomycin, 1mM sodium pyruvate and 10mM HEPES. G418 
is added to the LNCaP IGFBP5 medium. DU145 are maintained in αMEM with 10% 
FBS and 1% penicillin/streptomycin. RAS-NIH 3T3 and NIH 3T3 are maintained in 
DMEM with 10% Calf serum and 1% penicillin/streptomycin. PZ-HPV-7 cells are 
maintained in keratinocyte-SFM. 
4-Plasmid constructs: 
All Par-4 deletion mutants in pCB6+ (pCB6+-∆NLS1, pCB6+-∆NLS2, pCB6+-
204, pCB6+-185) were constructed by PCR amplification followed by ligation in pVP22-
TOPO or pcDNA3.1/CT-GFP-TOPO then left in the GFP plasmid or digested with XbaI 
and KpnI and subcloned into pCB6+. All used primers are shown in table (2.1). To delete 
the second NLS from pCB6+-NLS2 two more primer were used to amplify the fragment 
before the NLS2 (3' primer) and the fragment after the NLS2 (5'primer). An EcoRI site 
was inserted in these two primers (nucleotides in italics) and used to re-ligate the two 
fragments. 
All GFP fusion proteins were constructed by PCR amplification followed by 
ligation into pcDNA3.1/CT-GFP-TOPO or pcDNA3.1/NT-GFP-TOPO.  
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Table 2.1: Primers used in the construction of mutants. 
 Nucleotides not in the original sequence of Par-4 are shown in bold.  
Constructs 5' primer 3' primer 
∆NLS1 120GGAGGAGTGGAAAGCGAAG138 1264TGTTGAAAGACGGGGATTTACAC1242 
∆NLS2 120GGAGGAGTGGAAAGCGAAG138 
TTTTGAATTC532TCCACCGGCGTGGTCAA548
CTACGAATTC480GGCGCTGGGCCCCGAGC464
1264TGTTGAAAGACGGGGATTTACAC1242
148 508AGGAAGATGCGGGAGAAGC526 1264TGTTGAAAGACGGGGATTTACAC1242 
137 GAACATG478GCCAGGAAAGGCAAAG493 1264TGTTGAAAGACGGGGATTTACAC1242 
204 65CTGGGAACATGGCGACCG82 TC685AGGAGGTTCCTGGATCTGG667 
185 65CTGGGAACATGGCGACCG82 CTA627GATAGCATCCTCTCGCTTCC608 
GFP-Par-4 65CTGGGAACATGGCGACCG82 1063TCAGCTGCCCAACAACTTTC1044 
GFP- ∆NLS1 120GGAGGAGTGGAAAGCGAAG138 1063TCAGCTGCCCAACAACTTTC1044 
GFP- ∆NLS2 120GGAGGAGTGGAAAGCGAAG138 1063TCAGCTGCCCAACAACTTTC1044 
GFP-204 70AACATGGCGACCGGC84 TC685AGGAGGTTCCTGGATCTGG667 
GFP-∆ZIP 70AACATGGCGACCGGC84 TTA936TTTATCTTGCATCAGCCTCGT916 
GFP-137-
204 
GAACATG478GCCAGGAAAGGCAAAG493 679TTCCTGGATCTGGGAGGC662 
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1 GAATTCCAGG CGGCGGCGGC GGGAGTCAGG AGTCGCGGCG 
41 TGAGGGGCGC CCCCGCCGGC CCCTCTGGGA ACATGGCGAC 
81 CGGCGGCTAT CGGAGCAGCG GCAGCACCAC GGACTTCCTG 
121 GAGGAGTGGA AAGCGAAGCG CGAGAAGATG CGCGCCAAGC 
161 AGAACCCCGT GGGCCCGGGT TCGAGCGGCG GGGATCCAGC 
201 CGCCAAGTCC CCTGCGGGAC CGCTCGCCCA GACTACGGCC 
241 GCGGGGACCT CGGAACTCAA CCACGGCCCC GCCGGCGCGG 
281 CCGCACCTGC CGCCCCCGGG CCGGGCGCCC TGAACTGCGC 
321 TCACGGCTCG TCCGCGCTGC CCCGCGGGGC TCCCGGCTCC 
361 CGGCGGCCGG AGGACGAGTG TCCTATTGCC GCTGGGGCCG 
401 CGGGAGCACC CGCGTCCCGG GGAGACGAGG AGGAGCCGGA 
441 TAGCGCCCCG GAGAAGGGCC GCAGCTCGGG GCCCAGCGCC 
481 AGGAAAGGCA AAGGGCAGAT CGAGAAGAGG AAGCTGCGGG 
521 AGAAGCGCCG CTCCACCGGC GTGGTCAACA TCCCCGCGGC 
561 GGAGTGCTTA GATGAGTACG AAGATGACGA AGCAGGACAG 
601 AAGGAACGGA AGCGAGAGGA TGCTATCACA CAGCAGAACA 
641 CCATCCAGAA TGAAGCTGCG AGCCTCCCAG ATCCAGGAAC 
681 CTCCTACCTG CCCCAGGACC CGTCGAGAAC AGTCCCAGGC 
721 AGATACAAAA GCACAATCAG TGCCCCAGAA GAAGAAATCT 
761 TAAATAGATA TCCCCGAACA GATAGAAGTG GCTTCAGTAG 
801 ACACAACAGA GATACCAGTG CGCCTGCTAA CTTCGCTTCA 
841 AGTAGCACCT TGGAAAAGAG AATTGAAGAT CTTGAGAAGG 
881 AAGTCTTGAG AGAAAGGCAA GAAAACCTTC GACTTACGAG 
921 GCTGATGCAA GATAAAGAAG AAATGATTGG AAAACTCAAG 
961 GAAGAGATTG ATTTGTTAAA TAGAGACCTC GATGACATGG 
1001 AAGACGAAAA CGAGCAACTA AAGCAGGAAA ATAAAACTCT 
1041 TTTGAAAGTT GTTGGGCAGC TGACAAGGTA GAAGACGCAA 
1081 GGCTGCCTCG GTGTGGGAAA CCTGCTTTTAA ACCGCGGATG 
1121 AATGTCATGG CGAAGGCGCC CGTGATTCAG TGCGCTGAGA 
1161 GAACTGTATA TTTATTTCTA GAAAACACAT GGATCTCTTC 
1201 TTCTCAAAAT TTACTCTTTC TCATTACTAG TTTTTAAAAA 
1241 GTGTAAATCC CCGTCTTTCA ACATAGAAGT TAACATCTTT 
1281 AGCTATTAAA ATGATAGGTG ATGCCTCTTG GTTCTGTGTG 
1321 ATACTCAGAT AATATATGGT TCGAAGTAGC AGCCATTTGC 
1361 ATATGTTTTA TCTATGTTAG CACATATTCT CCCTAAAGGA 
1401 AGATGCATAG TCTTTGTTTA CATGAATTC 
 
Figure 0.1: Rat Par-4 cDNA.  
Par-4 open reading frame is 999 nucleotides. The start and stop codons are 
highlighted in gray. 
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A-PCR: The PCR reaction was set as follows: 
 29.7 µl distilled H2O. 
 8 µl of 1.25 mM deoxynucleotides mixture (dATP, dTTP, dGTP, dCTP).  
 5 µl 10X PFU buffer 
 4 µl template DNA (120ng) 
 5 µl 10X PCRx Enhancer solution 
 1 µl 5'primer 
 1 µl 3'primer 
 0.3 µl PFU turbo DNA polymerase. 
 50 µl total volume 
The PCR cycle was set as follows: 
Phase I  : 94ûC for 4' denaturing.  1 cycle 
Phase II :  94ûC for 4' denaturing. 
  62ûC for 1.2' annealing. 
  72ûC for 1.2' elongation.  30 cycles 
Phase III: 72ûC for 7'.    1 cycle 
 
B-Sub-cloning: 
DNA purification: After running 10 µl of the PCR product on a 0.7% agarose 
gel, the correct band was located and excised. Purification of DNA was performed by 
GFX PCR DNA and gel purification kit according to the manufacturer protocol as 
follows: To each 10 mg of the gel slice, 10 µl of capture buffer was added followed by 5-
15 minutes incubation at 60ûC. The melted agarose/buffer mix was then added to the 
GFX column placed in the collection tube. After 1' incubation at RT, the column was 
centrifuged for 30 seconds at maximum speed. The column was then washed with 500 µl 
wash buffer. The DNA sample was collected in a clean tube by adding 30-40 µl on the 
column and incubating for 1' at RT followed by 30 seconds centrifugation. 
Taq treatment: PFU turbo polymerase generates blunt end PCR products, which 
are unsuitable for TA-TOPO cloning where an "A" over-hang is required. To produce the 
A over-hang, the gel purified PCR product was subjected to Taq treatment as follows: 3.5 
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µl of 10X Taq polymerase buffer + 1 µl Taq polymerase + 1 µl 1mM dATP + 30 µl of 
gel purified PCR product. The mixture was incubated for 12' at 72ûC.  
Ligation: Directly after Taq treatment, ligation to TA-TOPO vectors was 
performed. A mixture of 3 µl of Tap treated DNA, 1 µl of the appropriate TA-TOPO 
vector and 1 µl 1.2 M salt solution, was incubated at room-temperature for a period of 
time varying between 5 minutes to 2 hours.  
Transformation of Escherichia coli: To a One Shot TOP10 competent cells 
tube, 2-5 µl of ligation mix was added then incubated on ice for 30 minutes. Heat shock 
was performed at 42ûC for 30 seconds then cells were immediately placed on ice for 2'. 
After adding 250 µl SOC medium (20 g bacto-tryptone, 5 g yeast, 0.5g NaCl, 10ml 250 
mM KCl and 20 mM glucose in 1 liter), cells were incubated at 37ûC for 1 hour with 
shaking than plated on LB ampicillin plates and incubated over-night at 37ûC. DNA was 
prepared from selected colonies by mini-prep using Gibco concert kit and examined after 
digestion with appropriate restriction enzymes, on an agarose gel. 
Sub-cloning in pCB6+: The pCB6+ vector and positive clones from the previous 
step are digested with the restriction enzymes XbaI and KpnI. The appropriate bands were 
isolated using GFX PCR DNA and gel purification kit. After the determination of the 
DNA concentration, vector and insert were mixed in the right molecular ratio then 2 µl of 
5x T4 ligation buffer + 0.2 µl of T4 ligation enzyme were added. Volume was adjusted to 
10 µl with distilled water. The mix was incubated over night at 16ûC. The following day, 
DHα bacteria were used for transformation by adding 1-5 µl of the ligation mix to 50 µl 
DHα and incubation 30 minutes in ice. Heat shock was performed at 37ûC for 20 second 
followed by 2 minutes incubation on ice. The mix was incubated for one hour in 900 µl 
SOC medium at 37ûC then plated on ampicillin LB agar plates. Following over night 
incubation at 37ûC, positive clones were identified by DNA mini-prep followed by 
restriction enzyme digestive. 
5-Transfection and Reporter Assays: 
Cells were plated in 6-well plates and transiently transfected the next day with the 
luciferase reporter system and various driver plasmids, along with CMV-β-galactosidase 
(β-gal) expression plasmid as an internal control. Transfections were performed using 
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lipofectamine plus from Invitrogen life technologies following the manufacturer protocol. 
DNA was diluted with 50µl of the appropriate serum free medium. I used 0.5-1µg of 
driver plasmids according to cell type, 0.3-0.35 µg of β-gal and 0.25 µg Gal4-luc + 
0.05 µg Gal4-RelA of the reporter system DNA. The mixture was incubated for 15 
minutes in room temperature (RT) after adding 6 µl of lipofectamine plus. Four µl 
lipofectamine reagent, diluted in 50 µl medium was added to the previous mixture and 
incubated for another 15 minutes. The cells' medium was replaced by 400 µl serum-free 
fresh medium before adding the transfection mix. Three hours later, the appropriate 
complete medium was added to the cells. For PC3 cells, transfection medium was 
removed first. The next day cells were split into two 96 well plates. After 48h, luciferase 
activity was determined in one plate using LucLite kit from Packard following the 
manufacturer protocol and the β-gal was determined in the other plate (detailed in 
Chapter III). The luciferase activity in each reaction was normalized with respect to the 
corresponding β-galactosidase activity. 
6-Indirect immunofluorescence:  
Cells were grown overnight in 8-chamber glass slides then transfected with the 
appropriate plasmid. Cells were fix for 30 minutes with 10% formaline in 1X PBS 24 or 
48 hours after transfection. After three washing in 1X PBS, cells were permealized with 
acetone for 6 minutes at 4ûC followed by three more washes. After one hour incubation in 
blocking solution (30 µl goat serum in 2.2ml 1X PBS), the appropriate antibody, diluted 
1:200 in blocking solution, was added to the cells for overnight incubation at 37ûC. The 
next day, cells were washed three times and incubated for one hour with the appropriate 
secondary antibody conjugated with the fluorescent dye Alexa Fluor 488 (green), 594 
(red) or Texas red all from Molecular Probes, Inc. followed by staining with propidium 
iodide (PI) or 4',6'-diamidino-2-phenylindole hydrochloride (DAPI) for 20 minutes for 
localization or apoptosis studies. Slides were washed 3 times with 1X PBS then air-dried. 
After adding an antifade (Vectashield from Vector Laboratories, Inc.), slides were 
covered with cover slips. Cells transfected with the GFP fusion proteins were not labeled 
with antibodies. They were first examined while still alive with a fluorescence 
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microscope then fixed and stained with DAPI or PI. Cells were examined with Confocal 
Scanning Microscopy for apoptosis and localization determination.  
7-Apoptosis assays:  
Apoptosis was determined by two methods. Initial screening was performed using 
TUNEL (terminal deoxynucleotide transferase-mediated dUTP-biotin nick end labeling) 
assay. Percentage of apoptosis was determined using DAPI. Cells plated in 8-chambered 
glass slides were transiently transfected with the appropriate plasmid. The untagged 
protein expressing cells were visualized by staining with anti Par-4 antibody followed by 
DAPI staining. Apoptotic nuclei were determined among transfected cells. Total 
transfected cells and transfected apoptotic cells are counted to determine percentage of 
apoptotic cells among cells expression ectopic Par-4 or mutants. EXCEL computer 
program was used for analysis and graph plotting. 
TUNEL assay: The TUNEL reaction mixture was prepared by mixing 50 µl of 
TUNEL enzyme with 450 µl of TUNEL label both from Roche. Cells were plated, 
tansfected and fixed as mentioned above in "4". Permeabilization was performed by 
adding 0.1% Na citrate/ 0.1% Triton X-100 on the slides and incubating for 2 minutes on 
ice. Slides were washed 3 times with PBS buffer then air-dried. Staining was performed 
by adding 30-50 µl of the TUNEL mix on cells in each chamber and incubating slides in 
humidified chambers for one hour at 37ûC in dark. Slides were then washed 3 times with 
1X PBS, air-dried, covered with antifade then with cover slips.  
8-Western blot analysis: 
Cells were harvested in Laemmli SDS-PAGE buffer [125 mM TrisHCl, pH 6.8, 
20% glycerol, 4% sodium dodecylsulfate (SDS) and 200 mM dithiothreitol (DTT)] 
(Laemmli, 1970) and proteins were separated on a 9% SDS-PAGE for 3-4 hours at 40 
mA using BioRad. Proteins smaller than 20 kD were separated on a 10% gel or for 2-3 
hour on 9% gel. Proteins were transferred to a PVDF membrane from Millipore using a 
BioRad transfer apparatus at 100V for 3 hours. After blocking in 5% milk, the membrane 
was probed with the appropriate antibody. The bands were visualized using ECL or ECL-
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Plus detection kits from Amersham Pharmacia biotech followed by exposure to X-ray 
films. 
 
RESULTS 
Ectopic Par-4 induces apoptosis only in cell lines in which it can translocate to the 
nucleus. 
Earlier histochemical studies showed that Par-4 localizes in the nucleus of 
prostate cells (Boghaert et al., 1997). However, subsequent cytochemical analysis of 
mouse fibroblast localized Par-4 in the cytoplasm (Berra et al., 1997). In PC12 cells, 
active Par-4 seemed to be localized in the cytoplasm (Guo et al., 1998a). No translocation 
of Par-4 was detected in NIH 3T3 mouse fibroblast cells, and removal of the NLS1 by 
deleting of the first 68 amino acids did not affect the function of Par-4 (Diaz-Meco et al., 
1999). On the other hand, sequence analysis of Par-4 reveals the presence of two putative 
nuclear localization sequences (Fig. 1.2 and 2.4 A). In addition, the ability of Par-4 to 
inhibit NF-κB transcriptional activity as well as binding to Dlk and WT1 support the 
notion of a nuclear function for Par-4. In agreement with this logic, we found that 
endogenous as well as ectopic Par-4 tend to translocate to the nucleus in androgen-
independent prostate cancer cell lines PC3 which are sensitive to direct induction of 
apoptosis by Par-4 (Fig. 2.2, 2.3 and data not shown). To determine Par-4 localization in 
different cell lines, I used indirect immunofluorescence analysis, in addition, I generated 
a Par-4-GFP fusion protein to confirm the localization in life cells. In all tested androgen-
independent prostate cancer cell lines (PC3, DU145, LNCaP IGFBP5) and transformed 
mouse fibroblasts (Ras NIH 3T3), Par-4 was found in nucleus as well as in the 
cytoplasm. On the other hand, androgen-dependent cells, like LNCaP have Par-4 strictly 
localized to the cytoplasm (Fig. 2.2). Endogenous Par-4 localization followed the same 
pattern in all tested cell lines. Both Par-4 and GFP-Par-4 showed similar results.  
Our group reported recently that over-expression of Par-4 is sufficient to directly 
induce apoptosis in androgen-independent cells (PC3, DU145) but not androgen-
dependent ones (LNCaP) (Chakraborty et al., 2001). Interestingly, all cells lines in which 
Par-4 can translocate to the nucleus were susceptible to apoptosis by Par-4. The newly 
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studied cell line LNCaP IGFBP5 gave results consistent with the conclusion reached so 
far. This cell line is derived from the androgen-dependent cell line LNCaP stably 
expressing insulin-like growth factor (IGF) binding protein-5 (IGFBP-5) (Miyake et al., 
2000) that renders it androgen-independent. LNCaP IGFBP5 is susceptible to apoptosis 
by Par-4 and in which Par-4 is present both in the nucleus and cytoplasm. Figure 2.2 
shows localization of Par-4 in LNCaP IGFBP5 and figure 2.3. shows apoptosis of this 
cell line compared to the previously determined PC3 and LNCaP (Chakraborty et al., 
2001). Localization of Par-4 relative to its ability to induce apoptosis was not restricted to 
prostate cancer cell lines but was found to be true in mouse fibroblasts as well (Fig. 2.2 
and table 2.2). We reported earlier that NIH 3T3 cells expressing oncogenic Ras are 
susceptible to apoptosis by Par-4 (Nalca et al., 1999). Table 2.2 summarizes the relation 
between Par-4 localization and ability to induce apoptosis in various tested cell lines. 
 
 
Table 2.2: Relationship between Par-4 localization and apoptosis in prostate 
cancer cell lines. 
PC3, DU145 and LNCaP IGFBP5 and androgen-independent prostate cancer cell 
lines. LNCaP is androgen-dependent prostate cancer cell line. PZ-HPV-7 is an 
immortalized prostate cell line and PrSc are primary stromal prostate cells. 
 
 PC3 LNCaP 
LNCaP 
IGFPB5 
DU145 NIH 3T3 
Ras 
NIH 3T3 
PZ-HPV-
7 PrSc 
Nuclear + - + + - + - - 
Cytoplasmic + + + + + + + + 
Apoptosis + - + + - + - - 
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Figure 2.2: Localization of Par-4 in different cell types. The figure shows 
localization of Par-4 and GFP-Par-4 in a number of human prostate cancer cell lines and 
mouse fibroblasts. Par-4 (green color) was visualized by Confocal Scanning Microscopy. 
Nuclei were stained with propidium iodide (red color). The left column shows Par-4 
alone and the right column is an overlay of the green Par-4 and the red nucleus. Yellow 
color indicated co-localization. 
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Figure 2.2: Localization of Par-4 in different cell types. 
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Figure 2.3: Apoptosis induction in selected prostate cancer cell lines. PC3, 
LNCaP and LNCaP IGFBP5 are transfected with GFP or GFP-Par-4 and fixed after 24 
hours. Nuclei are stained with DAPI. Cells were visualized using cells Confocal Scanning 
Microscopy. Apoptotic nuclei were identified among transfected cells.  
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Figure 2.3: Apoptosis induction in selected prostate cancer cell lines. 
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Par-4 Nuclear localization sequence affects its functions: 
Analysis of the primary protein sequence of Par-4 reveals the presence of two 
putative localization sequences (Fig. 2.4 A).  In my studies, I used rat Par-4, so all amino 
acids positions will be referring to the rat sequence. Positions of corresponding domain in 
mouse or human Par-4 can be found in Table 1.1. The first nuclear localization sequence 
(NLS1) lies between amino acids 20-25 (KAKREK) and the second (NLS2) lies between 
137-153 (RKGKGQIEKRKLREKRR) and it represents a classic bipartite nuclear 
localization sequence: Two adjacent basic amino acids (R or K), a spacer region of any 
10 residues, and at least three basic residues (R or K) in the five positions after the spacer 
region. 
In an attempt to understand the function of nuclear Par-4 and to find the 
sequences involved in Par-4 localization, two different deletion mutants were 
constructed. The first lacking NLS1, was constructed by deleting amino acids 1-25 
(∆NLS1). The second mutant (∆NLS2) starts from amino acid 25 and lack the sequence 
between amino acids 137-153, ie is missing both putative NLS' (Fig. 2.4 A). In addition, 
GFP fusion proteins of both mutants were constructed to facilitate detection of their 
localization. Deletion of NLS1 did not change localization or the apoptotic function of 
Par-4 (Fig. 2.5 A, 2.6). Figure 2.5 A shows the localization of ∆NLS1 by Confocal 
Scanning Microscopy to be similar to that of full Par-4, in addition two cells are showing 
typical apoptosis morphology of blebbing and condensed nuclei. Figure 2.6 shows the 
percent apoptosis induced by ∆NLS1. Interestingly, NLS1 seemed to be stronger than 
Par-4 in inducing apoptosis as will be discussed later, suggesting a potential inhibitory 
function for the first 25 amino acids. On the other hand, deletion of both nuclear 
localization sequences in ∆NLS2 completely abrogated the ability of Par-4 to translocate 
to the nucleus (Fig 2.5 B) and to induce apoptosis (Fig. 2.6).  
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Nuclear localization is required for induction of apoptosis and inhibition of NF-κB 
transcriptional activity: 
In an attempt to understand the nuclear role of Par-4, I analyzed the functions of 
Par-4 retained by ∆NLS1 and ∆NLS2 mutants. Full length Par-4 induces apoptosis in a 
number of cancer and transformed cell lines, inhibits RelA activity and regulates Fas 
membrane translocation. PC3 cells were transfected with ∆NLS1 or ∆NLS2. Percent 
apoptosis induction was determined using TUNEL, DAPI and PI staining using both 
pCB6+ and the GFP expression vector as control. The experiments were repeated with 
GFP tagged and untagged protein, which gave the same results confirming that the GFP 
tag did not interfere with the function of Par-4 or its mutants. Expression of the mutants 
in Ras NIH 3T3 gave same results as in PC3 (data not shown). Interestingly, not only did 
∆NLS1 retain the ability to induce apoptosis in PC3 and other Par-4 susceptible cells 
(Fig. 2.6 and data not shown), but it was also able to induce more apoptosis. The 
difference in percentage killing was not high but it was consistently reproducible. On the 
other hand, ∆NLS2 did not induce apoptosis above the background of GFP vector in any 
of the tested cell lines.  
Inhibition of NF-κB transcriptional activity by the mutants was determined using 
Luciferase reporter assay. The reporter system includes two constructs: one expressing a 
fusion protein between the transactivation domain of RelA (TA1) and Gal4 DNA binding 
domain. The other construct contains the Luciferase gene downstream of five Gal4 
binding site (Fig. 3.4). ∆NLS1, again, retained Par-4 ability to inhibit RelA 
transactivation, while ∆NLS2 was not able to perform this inhibition. Once again 
inhibition of RelA by ∆NLS1 was stronger than that of full length Par-4 (Fig 2.7). 
Finally, I examined at the ability of these mutants to regulate Fas. To our surprise 
both ∆NLS1 and ∆NLS2 were able to increase Fas translocation to the membrane (Fig. 
2.8). The ability of ∆NLS2 to cause Fas translocation implied that the mutations in 
∆NLS2 did not create a dead mutant but accurately targeted nuclear entry and nuclear 
functions. In addition, it suggested that Par-4 performs dual roles in the cytoplasm and in 
the nucleus and that it probably goes through complicated processes of regulation and 
activation both in the cytoplasm and in the nucleus. 
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NLS2 and not the adjacent sequences determines nuclear localization: 
Deletion of the 137-153 region disrupted three adjacent putative phosphorylation 
sites. One PKC phosphorylation site at 135 and two PKA sites at 154 and 155 (Fig. 1.1). 
To ascertain that the NLS2 and not the disrupted phosphorylation sites determine the 
nuclear translocation ability, two other mutants were constructed (Fig. 2.9 A). The first 
construct (137) started at amino acid 137 and retained NLS2 but not the 135 PKC 
phosphorylation site. This construct was able to translocate to the nucleus as shown in 
Figure 2.9 B. The second construct (148) started at amino acid 148, had NLS2 disrupted 
but retained the 154 and 155 PKA phosphorylation sites. This construct localized 
exclusively to the cytoplasm (Fig. 2.9 B). The results with the 137 and the 148 mutants 
proved that NLS2 is the nuclear localization sequence of Par-4 and that localization is not 
affected by the flanking phosphorylation sites. 
In summary, these results suggest that: a) NLS1 is not required for nuclear entry 
and that the first 25 amino acids of Par-4 sequence are dispensable Par-4 functions but 
they may contain an inhibitory/regulatory sequence. b)∆NLS2, which at first glance looks 
like a dead mutant, maintain the ability to regulate Fas. c)The failure of ∆NLS2 to induce 
apoptosis and inhibit RelA transactivation suggests that Par-4 nuclear entry is required 
for these functions while cytoplasmic Par-4 alone is capable of regulating Fas. Table 2.3 
summarizes the characteristics of the nuclear localization mutants of Par-4. 
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Figure 2.4: Nuclear localization mutants. 
A) Schematic presentation of full length Par-4 and the nuclear localization 
mutants ∆NLS1 & ∆NLS2 drawn to scale. ∆NLS1 starts at amino acid 26 and end at 332. 
∆NLS2 also starts at amino acid 26 but lacks the amino acids 137 to 153.  
B) Western blot of Par-4 and the NLS mutants. The left blot shows the expression 
of non-tagged protein. The right blot shows expression of GFP tagged protein, which 
roughly adds 26 kD. Both blots are probed with anti-par-4 antibody. 
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Figure 2.4: Nuclear localization mutants. 
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Figure 2.5: Localization of ∆NLS1 & ∆NLS2. Localization of the mutants was 
determined using indirect immunofluorescence assay or GFP tagged mutant together with 
PI staining of the nucleus.  
A) ∆NLS1 and GFP-∆NLS1 expressing cells were examined with Confocal 
Scanning Microscopy. The GFP-∆NLS1 expressing cell shows typical apoptosis 
phenotype namely condensed nucleus and membrane blebbing. 
B) ∆NLS2 and GFP-∆NLS2 localizes strictly to the cytoplasm.  
Both mutants gave same results in Ras NIH 3T3 cells. 
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Figure 2.5: Localization of ∆NLS1 & ∆NLS2. 
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Figure 2.6: Apoptosis induction by ∆NLS1 & ∆NLS2. Apoptosis percentage was 
determined by counting total transfected cells and the apoptotic cells as determined by 
condensed nuclei stained with DAPI or PI. GFP expressing cells were used as control. 
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Figure 2.6: Apoptosis induction by ∆NLS1 & ∆NLS2. 
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Figure 2.7: Effect of NLS mutants on RelA activity. PC3 or Ras NIH 3T3 cells 
were co-transfected with vector, Par-4, ∆NLS1 or ∆NLS2 expression plasmids together 
with the RelA reporter system. The cells were harvested 48 hr later and the prepared 
lysates were subjected to luciferase activity and β-galactosidase assays. Results were 
normalized to β-galactosidase expression. Vector control values were set to 1 and the 
other values were calculated relative to the vector value. 
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Figure 2.7: Effect of NLS mutants on RelA activity. 
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Figure2.8: Fas translocation by Par-4 and the NLS mutants. PC3 were transfected 
with vector, Par-4, ∆NLS1 or ∆NLS2 expression plasmids. After 24 hours, cells were 
fixed and incubated with anti Fas antibody followed by rabbit secondary antibody 
conjugated with Alexa Fluor 488 (green). Fas membrane translocation was detected by 
indirect immunofluorescent assays. 
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Figure 2.8: Fas translocation by Par-4 and the NLS mutants 
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Figure 2.9: NLS2 and not the flanking phosphorylation sites are responsible for nuclear 
localization of Par-4.  
A) Schematic presentation of full length Par-4, the 137 and 148 mutant drawn to 
scale. 137 lacks the 135 phosphorylation site but retains NLS2. 148 has NLS2 disrupted 
but intact S154 and T155 PKA phosphorylation sites.  
B) Immunofluorescence analysis shows that 137 has a localization similar to Par-
4 while 148 localization is identical to the cytoplasmic localization of ∆NLS2. 
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Figure 2.9: NLS2 and not the flanking phosphorylation sites are responsible 
for nuclear localization of Par-4. 
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Table 2.3: Comparison between the properties of Par-4 and NLS mutants. 
 
 
 
 
 
 Par-4 ∆NLS1 ∆NLS2 
Fas Regulation ++ ++ ++ 
RelA Inhibition ++ ++ - 
Localization Cyt/Nuc Cyt/Nuc Cyt. 
Induction of apoptosis ++ ++ - 
 
 
 
 
 
Cyt = Cytoplasmic localization. 
Nuc = Nuclear localization. 
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ANALYSIS OF THE C-TERMINUS OF PAR-4:  
The Leucine Zipper domain is not required for induction of apoptosis by Par-4 but 
affects its localization: 
After the determination of the nuclear localization sequence of Par-4 I started 
studying its other important and conserved domain: the leucine zipper domain. It is the 
region in the C-terminus of Par-4 between amino acids 292 and 332. A leucine zipper 
domain is an alpha-helical coiled coil structure stabilized by hydrophobic interaction. It is 
formed of heptad repeats with a hydrophobic amino acids at the first position and a 
leucine at the forth position. Leucine zippers mediate protein-protein interactions through 
hydrophobic interaction between the leucine residues. As predicted by Sells et al. (Sells 
et al., 1994), the leucine zipper domain of Par-4 is involved in binding to all currently 
known partners of Par-4, namely, WT1, ζPKC, p62 and Dlk. Deletion of the leucine 
zipper domain generates a mutant of Par-4 lacking amino acids 265 to 332 (∆Zip) (Fig 
2.10 A.) that is unable to sensitize melanoma cells to undergo apoptosis in response to 
apoptotic stimuli (Johnstone et al., 1996). Moreover, PC12 cells expressing ∆Zip are 
insensitive to Aβ1-42 or withdrawal of trophic factors (Guo et al., 1998a). In addition to 
the leucine zipper domain, it was suggested that the region from amino acid 248 to 330 
may be a death domain since it shows some degree of homology with death domains of 
RIP, FADD, TRADD and TNF receptor 1 (Diaz-Meco et al., 1996). 
Surprisingly, transient transfection of ∆Zip mutant in PC3 resulted in direct 
induction of apoptosis with efficiency slightly less than that of full length Par-4 (Fig. 
2.12) which can be explained by the lower expression of transfected ∆Zip compared to 
exogenous Par-4 (Fig. 2.10 B). This result suggested that although the leucine zipper 
domain of Par-4 is required for sensitization to apoptosis, direct apoptosis by Par-4 does 
not require the leucine zipper domain. This result also contradicts the idea of the presence 
of a death domain in the area between 248 and 330, which would be strongly disrupted 
by the deletion of the last 67 amino acids. Not only was ∆Zip able to induce apoptosis, it 
also retained some of the ability to inhibit RelA transcriptional activity (Fig. 2.13). The 
surprises revealed by ∆Zip did not stop at being a fully functional mutant. Confocal 
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analysis of ∆Zip revealed a localization pattern different than that of full length Par-4. 
Par-4 tends to first localize to the cytoplasm then translocates to the nucleus before cells 
die. At any given moment, there will be a mixture of cells with Par-4 in different 
compartments. On the other hand, ∆Zip has the same localization in all cells with 
predominant localization in the nucleus (Fig. 2.11). In conclusion, analysis of ∆Zip 
suggests that the leucine zipper domain and thus the currently known partners of Par-4 
are not required for induction of apoptosis or RelA inhibition and that it may be required 
for regulation of Par-4 localization.  
The leucine zipper domain includes a nuclear exclusion sequence: 
I was intrigued by the higher tendency of Par-4 to localize to the nucleus after 
deletion of the C-terminal 67 amino acids. It suggested that the leucine zipper domain 
plays a role in keeping Par-4 in the cytoplasm by binding to a cytoplasmic protein or by 
having a nuclear exclusion sequence (NES). A nuclear export sequence (NES) consists of 
a "leucine rich" sequence with the conserved consensus motif of four essential 
hydrophobic amino acids, a core tetramer typically of leucines and essential hydrophobic 
amino acids upstream and is recognized by Crm1p, a member of the β-karyopherin 
family (Fornerod et al., 1997). The bona fide form of NES is: L(x)2-3L(x)2-3LxL where 
L is leucine and x is any amino acid (Bogerd et al., 1996). Other proven NES have 
different hydrophobic amino acids (H) in places of the leucines. The general form is more 
like: HxxxH(x)2-3LxLx where L is leucine or isoleucine. Figure 2.14 shows NES from 
different proteins. Par-4 has a sequence between amino acids 291 and 302 that fits an 
NES-like sequence criteria. Par-4 sequence is MigkLkeeIdLl which satisfies all the 
requirements for NES. This sequence needs more analysis in order to identify its role in 
regulating Par-4 functions (Fig. 14). 
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Figure 2.10: C-terminus mutants of Par-4.  
A) Schematic presentation of full length Par-4 and the C-terminus mutants ∆Zip, 
204, 185 and 163 drawn to scale. All C-terminus mutants start at amino acid 1. 
B) Western blot showing endogenous Par-4 and the expression of ∆Zip.  
C) Western blot showing endogenous Par-4 and the expression of 204, 185 and 
163 mutants. 
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Figure 2.10: C-terminus mutants of Par-4. 
 
 73
 
Figure 2.11: Localization of C-terminus mutants of Par-4. Localization of the 
mutants was determined using indirect immunofluorescence assay or GFP tagged mutant 
together with PI staining of the nucleus. Cells were examined with Confocal Scanning 
Microscopy. All C-terminus mutants show higher tendencies to translocate to the 
nucleus. Figures shows PC3 cells but the mutants showed same localization in all tested 
cell lines. 
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Figure 2.11: Localization of C-terminus mutants of Par-4. 
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Figure 2.12: Apoptosis induction by C-terminus mutants. Apoptosis induction was 
determined as in figure 2.6. Percentage of apoptotic cells was calculated relative to total 
transfected cells. Comparable results were obtained in PC3 and Ras NIH 3T3 cell lines 
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Figure 2.12: Apoptosis induction by C-terminus mutants. 
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Figure 2.13: RelA inhibition by C-terminus mutants. RelA activity was determined as in 
figure 2.8. 
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Figure 2.13: RelA inhibition by C-terminus mutants. 
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Figure 2.14: NES in different proteins. 
 
 
 
 
 
         Core tetramer 
HTLV-1 REX L S A Q L Y S S L S L D 
PKI  L A L K L A G L D I N 
MEKK  L Q K K L E E L E L D 
HIV-1 REV   L P P L E R L T L D 
IκBα  M V K E L Q E I R L E 
PAR-4 M I G K L K E E I D L L 
             
Consensus for NES H X X X H X X X L/I X L/I X 
 
 
 
H = Hydrophobic amino acid 
X = Any amino acid 
L/I = Leucine or isoleucine amino acids 
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Par-4 loses activity after deletion of the 147 C-terminus amino acids: 
After discovering that the leucine zipper domain of Par-4 is not required for the 
investigated functions, I decided to make additional C-terminus deletion mutants in an 
attempt to localize the functional domains of Par-4 and the minimal functional region. A 
163 long deletion mutant of Par-4 (Fig. 2.10 A) was described in Sells et al. 1997 as Par-
4.∆CTH (Sells et al., 1997) where it was found unable to sensitize cells to apoptosis. In 
my hands, the 163 mutant failed to induce direct apoptosis or inhibit RelA transcriptional 
activity (Fig. 2.12 and Fig. 2.13) in all tested cell lines. In order to identify the region at 
which Par-4 loses its activity, I constructed two C-terminus deletion mutants termed 204 
and 185 (Fig. 2.10 A). All C-terminus mutants, including the earlier 163, had a 
localization pattern similar to ∆Zip as shown by Confocal Scanning Microscopy analysis 
of the GFP fusion protein and by indirect immunofluorescence of the untagged mutants 
(Fig. 2.11).  
Apoptosis studies performed by DAPI and PI in PC3 and Ras NIH 3T3 revealed 
that the mutant 204 is active while 185 is not. The ability to inhibit RelA transactivation 
went hand in hand with the ability to induce apoptosis (Fig. 2.12): 204 was able to induce 
inhibition while 185 could not (Fig. 2.13). It is important to note that 204 had a stronger 
ability to induce apoptosis compared to Par-4 (Fig. 2.12). Fas regulation analysis results 
were also consistent with the ability to induce apoptosis. As shown in table 2.3, 185 and 
165 did not affect Fas regulation.  
The studies performed on the C-terminus mutants confirmed that the leucine 
zipper domain is dispensable for apoptosis induction and that it plays a role in retaining 
most of Par-4 in the cytoplasm. In addition, deletion of 128 amino acids of Par-4 C-
terminus does not inhibit its studied functions. 
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Table 2.4: Comparison between the properties of Par-4 and C-terminus 
mutants. 
 
 
 
 ∆ZIP 204 185 163 
Fas regulation ++ ++ - - 
RelA inhibition ++ ++ - - 
Localization Nuc/Cyt Nuc/Cyt Nuc/Cyt Nuc/Cyt 
Induction of apoptosis ++ ++ - - 
 
Cyt = Cytoplasmic localization. 
Nuc = Nuclear localization. 
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A C-terminus regulatory domain: 
Assuming that the C-terminus of Par-4 has an inhibitory function, I decided to 
look at a possible acquired properties in 204. Transfection of 204 into the apoptosis 
resistant LNCaP cells revealed fascinating results. As expected 204 localizes mainly in 
the nucleus (Fig. 2.15), but unexpectedly 204 was able to induce apoptosis in LNCaP 
(Fig. 2.16, 2.17). This newly acquired function suggested that the C-terminus deleted part 
provides some regulatory function that is not functional in PC3 and other cells sensitive 
to full length Par-4 killing. Localization alone does not explain this ability to induce 
apoptosis because ∆Zip, which has the same localization, does not kill LNCaP (Fig. 
2.17). Unlike PC3, LNCaP has low NF-κB activity (Chakraborty et al., 2001) (Palayoor 
et al., 1999), so NF-κB inhibition is not likely to be the reason for apoptosis induction. 
On the other hand, part of the answer arose from the unique ability of 204 to increase Fas 
translocation in LNCaP (Fig. 2.18). Unfortunately, Fas translocation alone is not 
sufficient to induce apoptosis in LNCaP (Rokhlin et al., 1997) which suggests that 204 is 
activating an additional apoptosis mechanism(s) that is yet to be uncovered.  
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Figure 2.15: Localization of 204 in LNCaP cells. Cells were transfected with Par-
4 or 204 expression plasmids on chamber slides. After 24 hours, cells were probed with 
anti-par-4 antibody and nuclei stained with PI. Cells were examined by Confocal 
Scanning Microscopy.  
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Figure 2.15: Localization of 204 in LNCaP cells. 
 
 
 
 
 85
 
 
Figure 2.16: TUNEL of LNCaP cells. Cells were transfected with vector, Par-4 or 
204 expression plasmids on chamber slides. After 24 hours, apoptotic nuclei were labeled 
using TUNEL labeling system. Slides were examined with Confocal Scanning 
Microscopy. 
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 87
Figure 2.16: TUNEL of LNCaP cells. 
 
 
Figure 2.17: Apoptosis in LNCaP cells. Cells were transfected with GFP, Par-4, 
204 or ∆Zip on chamber slides. After 24 hours apoptosis percentage was determined as in 
figure 2.3. 
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Figure 2.17: Apoptosis in LNCaP cells. 
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Figure 2.18: 204 causes Fas translocation to the cell membrane of LNCaP cells. Cells 
were transfected with vector or 204 plasmids. After 24 hours, Fas translocation was 
identified using Confocal Scanning Microscopy as in figure 2.9. 
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Figure 2.18: 204 causes Fas translocation to the cell membrane of LNCaP 
cells. 
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A core sequence of 67 amino acids is fully functional: 
Since deletion of up to 136 N-terminus amino acids did not seem to change 
localization and apoptosis by the 137 mutants (137 expressing cell shows typical 
apoptotic morphology in figure 2.7 B) and the same was true for deleting C-terminus 
amino acids up to position 204, I suspected that the active domain of Par-4 may lie 
between amino acids 137 and 204. To test this idea I constructed a mutant lacking both C 
and N-terminal ends: 137-204-GFP (Fig. 2.19 A, B). I used the GFP fusion protein since 
the mutant is too small to be detected otherwise. In addition to having the nuclear 
localization sequence, this region has identical sequence in rat, mouse (137-205) and 
human (146-214) Par-4 except for the last nine amino acids that have one unmatching 
amino acid and three similar ones (Fig. 1.2). 
Confocal Scanning Microscopy examination revealed a nuclear localization 
preference similar to the other C-terminal mutants (Fig. 2.19 C) and typical apoptotic 
morphology. Apoptosis analysis showed that 137-204 is able to induce apoptosis with 
efficiency comparable to full length Par-4 (Fig. 2.20 A). Using the Luciferase reporter 
assay with the GFP expressing vector as the control 137-204 was found to inhibit RelA 
activity. Like 204, this small protein was also able to induce apoptosis in LNCaP but not 
in normal primary or immortalized cell lines such as PrSc and PZ-HPV-7. 
GFP-137-204 activities proved that Par-4 needs only this core region to perform 
its most important function, which is induction of apoptosis in cancer cells. The rest of 
the sequence probably provides some regulatory/inhibitory functions and/or some other 
roles related to Par-4 partner proteins that are not fully studied yet. In addition to the 
characterization of the active domain of Par-4, GFP-137-204 emphasized the findings 
done by the earlier mutants: 1) nuclear and cytoplasmic Par-4 are required for apoptosis 
induction, and 2) The leucine zipper domain is dispensable for the apoptotic function of 
Par-4. 
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Figure 2.19: GFP-137-204 expression and localization.  
A) Schematic presentation of full length Par-4 and GFP-137-204 construct drawn 
to scale. The GFP tag is represented by the broken green bar. 
B) Western blot, probed with anti-GFP antibody, showing GFP-Par-4 and GFP-
137-204 expression. .  
C) Confocal Scanning Microscopy images showing the predominantly nuclear 
localocalization of the mutant. Cells also show typical apoptotic phenotype. 
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Figure 2.19: GFP-137-204 expression and localization. 
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Figure 2.20: Induction of apoptosis and inhibition of RelA by GFP-137-204. 
A) A graph showing percent apoptosis induce by GFP-137-204.. GFP expression 
plasmid was used as a control. Apoptosis induction was determined like in figure 2.6. 
Percentage of apoptotic cells was calculated relative to total transfected cells. 
B) RelA inhibition by GFP-137-204. RelA activity was determined as in figure 
2.8. 
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Figure 2.20: Induction of apoptosis and inhibition of RelA by GFP-137-204. 
 
 
 
 96
 
DISCUSSION 
Par-4 is a pro-apoptotic protein with a complex mechanism of action with high 
potential for gene therapy. However, very little work has been done to understand the 
functional contribution of the different domains of Par-4 or its cellular localization. In 
order to study the localization and functional domains of Par-4, I made a number of 
constructs lacking key domains with and without GFP tags. The ability of Par-4 to 
translocate to the nucleus was found to correlate well with the ability to induce apoptosis 
in a panel of human and mouse cell lines that I tested. Although this observation should 
to be tested on a broader scale using diverse cell lines, the current findings strongly 
support an important role for nuclear localization. 
The use of GFP-Par-4 has many advantages over immunostaining: 1-It allows the 
analysis of live cells, albeit with a lower resolution fluorescence microscopy. In live cells, 
GFP-Par-4 is initially localized to the cytoplasm and over time increasing amounts 
translocate to the nucleus as the cell undergoes apoptosis. 2-GFP-Par-4 gives lower 
background than staining. 3-Immunostaining of transfected cells with the anti-Par-4 
antibody detects both exogenous and endogenous Par-4, while transfection with GFP-
fusion constructs allows detection of only the ectopic protein by fluorescence 
microscopy. 3-Use of GFP-Par-4 facilitates double and triple staining of other cellular 
proteins. On the other hand, the main draw back of using GFP-Par-4 is that it has shorter 
fluorescence life compared to stained proteins. 
The ability of Par-4 to specifically induce apoptosis in androgen-independent 
prostate cancer cell lines and not in androgen-dependent ones is not fully understood, but 
it may suggest a relation to the androgen receptor (AR). On the other hand, Par-4 induces 
apoptosis in estrogen-independent breast cancer cells and other hormone-independent 
cancers such as lung and head and neck cancer cell lines (data not shown). This suggests 
that sensitivity to Par-4 induced apoptosis may be related to how advanced the cancer is, 
and not to the presence or absence of a hormone receptor. In less advanced cancers Par-4 
regulation/inhibition is more intact than in more advanced ones. 
Localization of Par-4 to the nucleus was found to be mediated by the bipartite 
nuclear sequence NLS2, which is conserved in human, rat and mouse Par-4 sequences. 
Deletion of NLS2 uncovered the role of nuclear functions of Par-4. Cytoplasmic Par-4 
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cannot inhibit RelA transactivation but continues to affect Fas regulation, thus lack of 
NLS2 prevents induction of apoptosis, which requires both RelA inhibition and Fas 
membrane translocation. Other Par-4 functions are most probably disabled in ∆NLS2. 
More research is needed to identify these functions and their effects on Par-4 as an anti 
transforming agent. The identification of a role for Par-4 in the nucleus and the 
identification of a nuclear localization sequence raised several exciting questions. Since 
Par-4 has a NLS, why is it localized most of the time in the cytoplasm? What stops the 
NLS from functioning in androgen-dependent prostate cancer and normal cells? These 
questions need to be addressed in order to understand the mechanism of regulation of 
Par-4. 
Deletion from the C-terminus provided a number of interesting results. The 
leucine zipper domain that is involved in binding to WT1, ζPKC, p62 and Dlk is not 
required for direct induction of apoptosis, inhibition of RelA transactivation or Fas 
translocation. These results suggest that binding of Par-4 to these proteins serves 
functions other that those stated above. Some of Par-4 partners may be involved in 
regulation of Par-4 function or localization. The presence of a putative NES in the leucine 
zipper domain gives lots of support to such a hypothesis. Binding of Par-4 to Dlk results 
in translocation of the complex to the cytoplasm (Page et al., 1999). Although the 
significance of such a translocation is not known, it suggests that the regulation of 
localization of Par-4 or its partners may be controlled by their binding. On the other hand, 
one or more of the partner proteins may be binding to other domains of Par-4, in which 
case, some of these proteins may still be involved in the apoptotic function of Par-4. This 
possibility is supported by the fact that Par-4 was found to bind to two different domains 
of WT1 (Richard et al., 2001). Similarly, domains of Par-4, other than the leucine zipper 
domain, may be involved in protein-protein interaction functions. Another conclusion 
reached from studying the C-terminus mutants is the absence of the putative death 
domain (amino acids 248-330) suggested by Diaz-Meco et al. (Diaz-Meco et al., 1996), 
since deletion up to amino acid 204 still did not block induction of apoptosis. 
The most interesting and surprising results came with more extensive deletion of 
the C-end, which resulted in a protein more powerful than Par-4: 204 is able to induce 
apoptosis in the androgen-dependent cell line LNCaP. The sensitivity of LNCaP to the 
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new mutant may be due in part to the ability of 204 to regulate Fas translocation, 
although this alone, is not enough to induce apoptosis in LNCaP cells (Rokhlin et al., 
1997). Most likely, a second apoptotic pathway is activated that, together with Fas, 
induces apoptosis in LNCaP cells. Par-4 is known to affect regulation of both Fas and 
FasL in sensitive cell lines. In LNCaP cells, 204 may be increasing membrane 
translocation of Fas and FasL, and their over-expression, inside the LNCaP cells, have 
been shown to induce apoptosis (Hyer et al., 2000). 
Deletion analysis of Par-4 suggests the presence of more than one 
inhibitory/regulatory domain. The characteristics of ∆NLS1 mutant suggest that such a 
domain may be present in the first 24 amino acids of Par-4. The ability of ∆NLS1 to 
induce more apoptosis and inhibition of RelA cannot be explained by the level of protein 
expression since, in general, ∆NLS1 tends to be expressed in amounts less than that of 
ectopic full length Par-4 (Fig. 2.4 B). The leucine zipper domain can also be classified as 
an inhibitory/regulatory domain since its deletion favors translocation of Par-4 to the 
nucleus, which is an essential step in the apoptotic action of Par-4, as I have shown 
above. Another inhibitory/regulatory domain may also be located between 205 and 265 
since deletion of this region allows 204 to extend its apoptotic potential to cell lines 
resistant to full length Par-4.  
In summary, my work shows that: 1) Par-4 must translocate to the nucleus to 
inhibit RelA transcriptional activity and to induce apoptosis, 2) Cytoplasmic Par-4 is 
required for Fas translocation to the membrane, 3) A core 67 amino acids sequence of 
Par-4 is sufficient to induce apoptosis and it has a wider range of action in prostate cancer 
cell lines than full-length Par-4, 4) The C and N-terminus of Par-4 contains 
regulatory/inhibitory domains that need further investigations. 
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CHAPTER 3 
POSSIBLE MECHANISMS OF INHIBITION OF RELA BY PAR-4 
NF-κB is a general name for a large family of transcription factors formed by 
dimerization between members of the Rel family (Fig. 3.1) and bind to a common DNA 
sequence known as κΒ sites. NF-κB crucial role in inflammation and immune response is 
well established. It was discovered as a constitutive nuclear transcription factor in mature 
B cells that bound to an element in the kappa immunoglobulin light-chain enhancer (Sen 
and Baltimore, 1986). Activation of the NF-κB pathway is normally triggered by 
microbial or viral infections and exposure to mitogens, double-stranded RNA, UV light 
or proinflammatory cytokines, which results in the activation of the transcription of a 
number of key cytokines and cytokine receptors (Barnes and Karin, 1997). In addition to 
its role in the immune system NF-κB has an important regulatory role in apoptosis 
(Barkett and Gilmore, 1999) and cell proliferation (Perkins, 2000). It antagonizes 
apoptosis by enhancing the expression of some anti-apoptotic proteins like Inhibitor of 
Apoptosis Proteins (IAPs), FLICE inhibitory protein (cFLIP) and members of Bcl-2 
family like BclX, and affects proliferation by increasing the transcription of genes such as 
c-myc and cyclin D1. 
Considering NF-κB positive role in inflammation, cell proliferation and survival, 
it is no surprise that NF-κB plays an important role in oncogenesis and in the resistance 
of tumor cells to chemotherapy (Rayet and Gelinas, 1999). Disruption of the tightly 
controlled activation of NF-κΒ favors cellular transformation. NF-κB is required by some 
oncogenes, such as Ras, for accomplishing transformation (Finco et al., 1997) (Perkins, 
2000). There are several mechanisms by which NF-κB transcription factors are 
uncoupled from their normal modes of regulation, and these have been associated with 
cancer. The first evidence that linked NF-κB to cancer was the v-Rel oncoprotein of the 
REL retrovirus (REV-T) which is a very potent transforming agent in avian and 
mammalian cells (Gilmore, 1999a). v-Rel has accumulated enough mutation to become a 
constitutively active transcription factor. Cancer-associated chromosomal translocations, 
deletions and mutations participate in disrupting genes that encode NF-κB and ΙκB 
proteins, uncoupling NF-κB factors from their regulators and causing constitutive NF-κB 
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activation. Production of proinflammatory cytokines, oncogenic activation of upstream 
signaling molecules and chronic infections have been shown to persistently stimulate 
IKK activity, which leads to constitutive NF-κB activation (Karin et al., 2002).  
Rel proteins form a family based on extensive structural similarity within a 
domain of about 300 amino acids called the Rel homology domain (RHD) (Fig 3.2). This 
domain is involved in dimerization between the members of the Rel family, DNA and 
IκΒ binding and nuclear localization. Rel family members can be divided into two classes 
(Fig. 3.2). Class I members are synthesized as large precursor with ankyrin repeats at the 
C-terminus that is cleaved for activation and an RHD at their N-terminus. This class 
includes NF-κB1 (precursor of p52) and NF-κB2 (precursor of p50). Class II members 
have an RHD and most importantly a transactivation domain at there C-terminus. Class II 
includes RelA, c-Rel, RelB (Gilmore, 1999b). 
The most prominent form of NF-κB is a heterodimer between the subunits RelA 
and p50. In its inactive form, NF-κB is held captive in the cytoplasm by binding to the 
ankyrin repeats contained within the inhibitor protein IκB. In response to various stimuli, 
NF-κB can be activated at two different levels. The first involves activation of the IKK 
complex resulting in IκB phosphorylation and its subsequent degradation and the release 
of NF-κB. The latter is then free to translocate to the nucleus, where it binds to κB 
sequences and activates the transcription of specific genes (Baldwin, 1996). The second 
level of activation involves changes, such as phosphorylation in the RelA subunit that 
enhances its transcriptional activity. 
Ras and Raf have been known to activate NF-κB quite efficiently, but, despite 
vigorous efforts, the mechanism has remained elusive. Many of the pathways activated 
by Ras and Raf have been implicated in NF-κB activation. Some activation will occur by 
the phosphorylation and subsequent degradation of IκB by kinases such as Akt/protein 
kinase B (Ozes et al., 1999), RSK, an ERK-activated protein kinase, (Ghoda et al., 1997), 
and others. More evidences suggested Ras affecting NF-κB by activation of RelA, which 
will be discussed in the following section. 
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Figure 3.1: Mammalian Rel family members. With a few exceptions, all NF-κB 
subunits homo- and heterodimerize. Most NF-κB complexes are retained inactive in the 
cytoplasm by binding to IκB. Some NF-κB complexes, such as p52¯RelB do not bind 
IκB and translocate directly to the nucleus. p100 and p105 must undergo proteolytic 
processing to remove their inhibitory IκB-like ankyrin repeat (ANK) domains. 
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Figure 3.1: Mammalian Rel family members. 
 
C
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Figure 3.2: Schematic representation of RelA showing the Rel homology domain (RHD) 
as a gray box. NLS is the nuclear localization sequence. TA is the transactivation domain. 
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Figure 3.2: Schematic representation of RelA.  
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RelA activation 
RelA subunit is a 551 amino acids protein that has a RHD, nuclear localization 
sequence (NLS) and 2 transactivation domains at its C-terminus: TA2 and TA1 (Fig. 3.2). 
RelA has various phosphorylation sites that are involved it is activation. Over the last few 
years, activation of NF-κB by RelA phosphorylation has acquired increasing weight. 
Numerous signals that have been known to phosphorylate IκΒ, enhance NF-κB nuclear 
translocation and DNA binding, have been also shown to increase RelA transcriptional 
activity by phosphorylation. TNF-α was found to increase RelA activity by 
phosphorylating serine 529 in its TA1 domain (Wang and Baldwin, 1998). Shortly after, 
Vanden Berghe et al. reported that full activation of RelA by TNF-α requires both 
activation domains (TA1, TA2) and might be mediated by the MAP kinases p38 and 
ERK (Vanden Berghe et al., 1998).  
RelA is also phosphorylated by ζPKC at serine 276 (Anrather et al., 1999). This 
same site is phosphorylated by PKA as well and it is suggested that this phosphorylation 
allows the unfolding of the RelA and the unmasking of two p300 binding site leading to 
p300 binding and full activation of RelA (Zhong et al., 1998). Over-expression of IKK 
complex or its activation by TNF-α results in phosphorylation of RelA at serine 536 in 
the TA1 domain (Sakurai et al., 1999). Ras activation has been repeatedly shown to 
increase RelA transcriptional activity without affecting IκB phosphorylation or NF-κB 
binding to DNA. Activation by Ras can occur through MAP kinases (Norris and 
Baldwin, 1999), ζPKC (Anrather et al., 1999), AKT/PKB (Madrid et al., 2000) and 
maybe other means still to be discovered. These data revealed the dual role played by 
different kinases in activation of NF-κB such as the IKK complex (Sizemore et al., 2002) 
and ζPKC in NF-κB activation (Anrather et al., 1999, Moscat et al., 2001). 
The extracellular signal-regulated kinases (ERKs) are one family of the mitogen-
activated protein (MAP) kinases. They are ubiquitous serine/threonine protein kinases 
that lie in a signaling pathway downstream of the Ras in the Ras-Raf-MEK (MAPK/ERK 
kinase)-ERK cascade. These kinases are involved in signaling cascades from membrane 
to nucleus that regulate a number of cellular pathways, including the control of cell 
proliferation, differentiation, transformation and apoptosis (Kolch, 2000). The two best-
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characterized ERKs, ERK1 and ERK2, are activated by phosphorylation on threonine and 
tyrosine within the kinase domain. Upon mitogen stimulation of the cell, the ERKs are 
quickly phosphorylated by the MEKs and a portion of the active ERK population 
translocates to the nucleus (Chen et al., 1992). The role of ERK in activation of NF-κB 
has been a little controversial. The ability of the Ras-Raf segment to activate NF-κB 
suggests a role for ERK. As mentioned above, TNF-α activates RelA in an ERK 
dependent fashion. ERK is involved in Okadaic acid enhancement of RelA 
transactivation in monocytes (Tuyt et al., 1999). On the other hand, Carter and 
Hunninghake reported that constitutive active MEK-ERK inhibits RelA activation by 
inhibiting the phosphorylation of TATA binding protein (TBP) required for RelA 
transcription activity (Carter and Hunninghake, 2000). 
The p90 RSK family members are serine/threonine kinases activated in response 
to mitogenic signals by a series of phosphorylations carried out by ERK. Although for a 
long time RSK were mainly considered as ERK substrate, it can be phosphorylated and 
activated by other kinases such as 3-Phosphoinositide-dependent kinase 1 (PDK1), and 
RSK themselves (Frodin and Gammeltoft, 1999) (Williams et al., 2000) (Frodin et al., 
2000) (Merienne et al., 2000). RSKs were originally identified as protein kinase activities 
that could phosphorylate the S6 protein of the 40 S subunit of the ribosome in vitro, 
hence the name Ribosomal S6 kinases (RSKs) (Erikson and Maller, 1985). This turned 
out to be true in Xenopus oocytes but not in other cell types. RSKs have been implicated 
in (1) Regulation of gene expression via association and phosphorylation of 
transcriptional regulators including IκΒα (Ghoda et al., 1997) (Schouten et al., 1997), 
cAMP-response element-binding protein (CREB) and CREB-binding protein(CBP) 
(Xing et al., 1996) (Nakajima et al., 1996) ; (2) Cell cycle regulation in Xenopus laevis 
oocytes (3) RSK may regulate protein synthesis by phosphorylation of polyribosomal 
proteins and glycogen synthase kinase-3 (GSK3) (Torres et al., 1999); and (4) RSK 
phosphorylate the Ras GTP/GDP-exchange factor, Sos leading to feedback inhibition of 
the Ras-ERK pathway. In mammalian cells there are three isoforms of RSK (RSK1, 
RSK2, RSK3), whose functional specificity remains undefined (Frodin and Gammeltoft, 
1999).  
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Par-4 inhibits Ras and TNF-α activated NF-κB: 
A role in NF-κΒ regulation was suggested from the ability of Par-4 to induce 
apoptosis in Ras transformed cells and its binding to aPKC. Both Ras and ζPKC (a 
member of aPKC) are well established activator of NF-κB. Earlier work from our group 
showed that Par-4 inhibits Ras activated NF-κB. This inhibition did not affect IκB, NF-
κB nuclear translocation or DNA binding. Par-4 inhibition was directed to the 
transcription activity of the RelA subunit (Nalca et al., 1999). On the other hand, Dias-
Meco el al. showed that Par-4 inhibits TNF-α induced NF-κB nuclear translocation and 
DNA binding (Diaz-Meco et al., 1999). Inhibition of TNF-α survival pathway by Par-4 
result in induction of apoptosis. In this report it was suggested that Par-4 inhibits NF-κB 
by binding and inhibiting aPKC. The latter are known to activate NF-κΒ by numerous 
mechanisms. Different signals induce binding of aPKC to IKK complex leading to 
activation of IKKβ and subsequent activation of NF-κB (Lallena et al., 1999) (Moscat 
and Diaz-Meco, 2000). As mentioned earlier, ζPKC can also directly phosphorylate and 
activate RelA (Anrather et al., 1999). In addition, ζPKC can directly bind RelA (Leitges 
et al., 2001). 
In this chapter, I will discuss parts of an unfinished project directed towards the 
identification of the mechanism by which Par-4 inhibits the transcription activity of 
RelA. Despite the promising results obtained in this work, the more demanding and 
exciting studies of the structure and function of Par-4 took over. Nevertheless, this work 
provided me with a better understanding of some signal transduction systems. In this 
project I discovered ERK acts on the TA1 to enhance the activity of RelA and that its 
function is essential, at least, for the Ras activated RelA. In addition, I discovered an 
additional mechanism by which ζPKC can activate NF-κB and that RSK activates RelA 
as well. 
MATERIALS AND METHODS 
1-Plasmids:  
pCB6+ (a derivative of pCB6 (Gashler et al., 1993)), pCB6+-Par-4, CA-ERK and 
dnERK-2 from Dr. Melanie Copp (Department of Pharmacology University of Texas 
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Southwestern Medical Center), wt-RSK from Dr. Jim Maller (Howard Hughes Medical 
Institute, University of Colorado School of Medicine), dnRSK from Dr. Alt Zantema 
(Leiden University, Leiden, The Netherlands). pSVβgal from Dr. Brett Spear 
(Microbiology & Immunology, University of Kentucky), The Gal4 Luciferase (Gal4-
Luc) constructs contain four Gal4 DNA consensus binding sites derived from the 
Saccharomyces cerevisiae located  upstream of luciferase reporter gene, and Gal4-p65 
constructs have the yeast Gal4 DNA binding domain fused to the transactivation domain 
(TAD) of p65 both from Dr. A. Baldwin (University of North Carolina at Chapel Hill, 
Chapel Hill, NC). ζPKC from Dr. J. Moscat (Centro de Biologia Molecular Severo 
Ochoa, Universidad Autonoma Spain). 
2-Transfection and Reporter Assays: 
 Cells were transiently co-transfected with the luciferase reporter system (Gal-4-
Luc and Gal-4-p65519-551) and various driver plasmids, along with CMV-β-galactosidase 
expression plasmid for an internal control. Transfections were performed using 
lipofectamine plus from Invitrogen Life Technologies following the manufacturer 
protocol. DNA was diluted with 50µl of the appropriate serum free medium. I used 0.5-
1µg of driver plasmids according to cell type, 0.3-0.35 µg of β-gal and 0.25 µg Gal4-luc 
+ 0.05 µg Gal4-RelA of the reporter system DNA. The amount of DNA used in each 
experiment was made equal by addition of the vector pCB6+. The mixture was incubated 
for 15 minutes at room temperature (RT) after adding 6 µl of lipofectamine plus. Four µl 
lipofectamine reagent, diluted in 50 µl medium, were added to the previous mixture and 
incubated for another 15 minutes. The medium was replaced by 400 µl serum-free fresh 
medium before adding the transfection mixture. Three hours later, the appropriate 
complete medium was added to the cells. For PC3 cells, transfection medium was 
removed before adding the complete medium. The next day cells were split into 96 well 
plates and subjected to the appropriate treatment such as addition of inhibitors. 48h after 
transfection, luciferase activity was determined using LucLite kit from Packard following 
the manufacturer protocol. Cells were washed 3 times with 1X PBS then lysed by 
incubation for 20-30 minutes with 75 µl of LucLite substrate buffer solution. After lysis 
was completed, 80 µl of 1X PBS with 1 mM magnesium and 1mM Calcium were added 
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followed by 50 µl of LucLite substrate reconstituted in 5 ml of LucLite buffer. 
Preparation of substrate and all subsequent steps were performed in dark. After addition 
of substrate, 200 µl of the cell mixture from each well was transferred to a 96 well 
optiplate from Packard where it was incubated for 10 minutes in dark. The Luciferase 
luminescence was read using a "Microplate Scintillator Counter" from Packard. The β-
galactosidase activity was determined using ONPG (o-nitrophenyl-beta-D-
galactopyranoside) solution (0.1g ONPG +0.0585 g Na2HPO4 + 0.065 NaH2PO4 in 50 
ml of distilled water adjusted to pH 7.8+/- 0.5). Before use, β-Mercaptoethanol was 
added to the ONPG solution to a final concentration of 0.046M. Cells in 96 well plates 
were lysed with 35 µl lysis buffer (10 mM Tris, 150 mM NaCl, 50 mM NaF, 1 mM 
Na3VO4 and 0.5% NP-40 after adjusting pH to 7.6 in 500ml.Protease inhibitors were 
added before use). Plates were vortexed briefly then incubated on ice for 10 minutes. The 
lysed vortex-incubation cycle was repeated for 3 times before the addition of 200 µl of 
the ONPG solution. Plates were incubated at 37ûC till the development of an appropriate 
yellow color. The intensity of the β-galactosidase activity was measured by an ELISA 
reader at a wavelength of 405. The luciferase activity in each reaction is normalized with 
respect to the corresponding β-galactosidase activity.  
3-Cells: 
iRas NIH 3T3 were maintained in DMEM with 10% FBS and 1% penicillin/ 
streptomycin. These cells have an inducible H-Ras gene that is expressed when cells are 
treated with IPTG (isopropyl-beta-D-thiogalactopyranoside). PC3 were maintained in 
RPMI 1640 with 10% FBS and 1% penicillin/streptomycin. 
4-Antibodies:  
Polyclonal antibodies for Par-4, RelA, ζPKC, ERK and RSK were from Santa 
Cruz Biotechnology, Inc.  
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RESULTS 
ERK increases the transactivation properties of RelA:  
Earlier work from our group revealed the ability of Par-4 to inhibit the 
transcriptional activity of RelA induced by Ras. This inhibition was independent of NF-
κB translocation to the nucleus or its binding to the DNA since the IκB degradation did 
not increase and the electromobility shift assay did not show an increase in NF-κB 
binding to DNA (Nalca et al., 1999). In an attempt to understand the mechanism of this 
inhibition I investigated pathways activated by Ras. I decided to study the Ras-Raf-ERK 
pathway because of the strong relationship it has with Par-4. Par-4 inhibits Ras and Raf 
induced NF-κB activity. Unlike Ras, Raf activation of NF-κB does not include IκB 
degradation or DNA binding which implies it may occur on the RelA level (Nalca et al., 
1999). In addition, in the presence of Ras, over-expression of Par-4 down-regulates total 
levels of ERK1/2 (Fig. 3.3) (Qiu et al., 1999b).  
In order the study the role of ERK in the activation of RelA I used a reporter 
system that bypasses activation modes involving IκB degradation and DNA binding (Fig. 
3.4). This system is composed of a fusion protein between Gal4 DNA binding domain 
and the TA1 domain of RelA. This construct does not have the RHD or the DNA binding 
domain of RelA so it only studies the regulation exerted on the TA1 domain of RelA. The 
Gal4-RelA fusion protein drives the expression of a luciferase gene located downstream 
of a Gal-4 binding sequence. To detect a possible involvement of the MEK-ERK pathway 
in RelA activation I started by inhibiting the pathway using the MEK inhibitor PD98059. 
I co-transfected the cells with Gal-4-luc reporter system and the driver plasmid, which in 
this case is the empty vector, then left them untreated or treated them with the PD98059 
(Fig. 3.5). The inhibition the ERK pathway strongly inhibited RelA activation. Since the 
inhibitory effect of PD98059 may not be very specific I then co-transfected the cells with 
a constitutively active ERK-2 (CA-ERK) (Robinson et al., 1998). This construct 
expresses a fusion protein between ERK-2 and MEK-1 to allow a constitutive activation 
of ERK-2. Over-expression of CA-ERK resulted in a large increase in RelA activity. Co-
expression of equal amounts of CA-ERK and Par-4 resulted in inhibition of the RelA 
suggesting that Par-4 acts downstream of ERK activation (Fig. 3.6). The effect of ERK 
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on RelA was further emphasized by co-transfection with a dominant negative ERK-2 
(dnERK) expression vector that resulted in a very strong inhibition of RelA activity (Fig. 
3.6). The ability of ERK to enhance RelA transcriptional activity was confirmed in other 
cell lines such as the human prostate cancer cell line PC3 (Fig. 3.7).  
The importance of these results is that it proved the strong ability of ERK to 
enhance the transcriptional activity of RelA. In addition, it narrowed down the site of 
action of ERK to the TA1 domain and suggests that TA2 may not be essential for the 
action of ERK on RelA. The strong inhibition achieved by the inhibitor PD98059 and a 
dominant negative mutant in Ras expressing NIH 3T3 suggests that ERK is required for 
Ras induced RelA activation. In addition these data suggested that Par-4 acts downstream 
of ERK to inhibit RelA activity. 
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Figure 3.3: Par-4 inhibits ERK in a Ras dependent manner. iRas cells express 
oncogenic Ras when exposed to IPTG. Expression of oncogenic Ras results in ERK2 
phosphorylation. Co-expression of Par-4 with oncogenic Ras, down-regulates ERK2 as 
well as phospho-ERK2. 
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Figure 3.3: Par-4 inhibits ERK in a Ras dependent manner. 
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Figure 3.4: The Gal4-RelA reporter used to measure RelA transactivation. The reporter 
system is composed of two plasmids. The first one (upper panel) expresses a fusion 
protein between the Gal4 DNA binding domain and the TA1 domain (519-521) of RelA. 
The second plasmid (lower panel) contains five Gal4 binding sites upstream of the 
Luciferase reporter gene. Binding of the fusion protein to the DNA drives expression of 
the Luciferase gene. 
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Figure 3.4: The Gal4-RelA reporter system.  
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Figure 3.5: ERK is required for RelA activation by Ras. Ras NIH 3T3 cells were 
transfected with vector together with the RelA reporter system. PD98059 was added after 
24 hours. The cells were harvested 48 hours after transfection and the prepared lysates 
were subjected to luciferase activity and β-galactosidase assays. Results were normalized 
to β-galactosidase expression. The Luciferase activity is represented as relative values 
where the untreated control value has been set to one. 
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Figure 3.5: ERK is required for RelA activation by Ras. 
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Figure 3.6: Par-4 acts downstream of ERK. Over-expression of constitutive 
active ERK2 (CA-ERK) cause strong activation of the RelA TA1 domain. Par-4 co-
expression overcome ERK2 activation. The function of ERK2 is emphasized by ability of 
dominant negative ERK2 (dn-ERK) to inhibit RelA activation. 
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Figure 3.6: Par-4 acts downstream of ERK. 
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Figure 3.7: RelA activation by CA-ERK in PC3. PC3 cells were transfected with vector 
or CA-ERK together with the RelA reporter system. The cells were harvested after 48 
hours and Luciferase activity determined as in figure 3.5. The Luciferase activity is 
represented as relative values where the untreated control value has been set to one. 
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Figure 3.7: RelA activation by CA-ERK in PC3. 
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RSK over-expression enhances the transactivation properties of RelA: 
Searching for the mechanism by which REK can activate RelA, I decided to look 
at a possible role for RSK since it is a known substrate of ERK. Activation of ERK leads 
to activation of RSK in essentially all cases where both kinase activities have been 
measured which can be partially explained by the physical association between the two 
kinase (Frodin and Gammeltoft, 1999). RSK is also involved in NF-κB activation by 
causing ΙκΒ phosphorylation. Transfecting cells with the RelA reporter system and a wild 
type expression RSK vector resulted in a strong increase in RelA activity in all tested cell 
lines. Par-4 co-transfection inhibited RelA activation by RSK, again suggesting that Par-4 
acts downstream of RSK (Fig. 3.8). The expression of CA-ERK and RSK plasmids is 
shown in Figure 3.9. Positioning of RSK downstream of ERK was not that clear. Using a 
dominant negative RSK1 expression vector (dnRSK1) (Schouten et al., 1997), did not 
result in the same degree of inhibition as seem with dnERK (Fig. 3.10). IκBα 
phosphorylation is accomplished by RSK1 and an over-expression of the dnRSK inhibits 
phosphorylation and degradation of IκBα. Other RSKs (RSK2 or RSK3) may be 
involved in activation of RelA TA1 domain. In such cases dnRSK1 will not be able to 
inhibit other RSKs activity, which may explain the weak inhibition accomplished by 
dnRSK1. On the other hand, another clue that ERK and RSK may be using different 
mechanisms to activate RelA came from using a Gal4-p65 mutant harboring a S to A 
mutation at position 529. The phosphorylation of S 529 has been shown to be involved in 
activating RelA by TNF-α. CA-ERK activation was abolished by this mutation, which is 
consistent with reports suggesting that TNF-α activation is mediated by MAP kinases 
(Vanden Berghe et al., 1998). On the other hand, RSK ability to activate RelA was not 
affected by the 529 mutation (Fig. 3.11). ERK is not the only activator of RSK, which 
can be activated by other kinases such as PDK1. This suggests that RSK can be involved 
in the activation of RelA through a different pathway that is yet to be identified. 
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Figure 3.8: Par-4 acts downstream of RSK. Ras NIH 3T3 or PC3 cells were 
transfected with vector, Par-4, RSK or Par-4+RSK together with the RelA reporter 
system. The vector plasmid was used to normalize the amount of transfected DNA. The 
cells were harvested 48 hours after transfection and the luciferase activity determined as 
in figure 3.5. The Luciferase activity is represented as relative values where the untreated 
control value has been set to one. 
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Figure 3.8: Par-4 acts downstream of RSK. 
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Figure 3.9: Expression of constitutive active ERK and RSK in transfected cells. Ras cells 
were transiently transfected with CA-ERK or RSK. After 24 hours cells were harvested 
and lysate were examined by Western.  
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Figure 3.9: Expression of constitutive active ERK and RSK. 
 
 
  
B A 
 127
 
Figure 3.10: Inhibition of RelA by dominant negative expression vectors of ERK and 
RSK. Ras NIH 3T3 cells were transfected with the appropriate plasmids together with the 
RelA reporter system and harvested 48 hours after transfection. The prepared lysates 
were subjected to luciferase activity and β-galactosidase assays. Results were normalized 
to β-galactosidase expression. The Luciferase activity is represented as relative values 
where the untreated control value has been set to one. 
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Figure 3.10: Inhibition of RelA by dominant negative expression vectors of 
ERK and RSK.  
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Figure 3.11: Activation of RelA TA1 and mutant 529 TA1 domain by CA-ERK and 
RSK. Ras NIH 3T3 cells were transfected with the appropriate plasmids and harvested 48 
hours after transfection. The prepared lysates were subjected to luciferase activity and β-
galactosidase assays. Results were normalized to β-galactosidase expression. The 
Luciferase activity is represented as relative values where the untreated control value has 
been set to one. 
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Figure 3.11: Activation of RelA TA1 and mutant 529 TA1 domain by CA-
ERK and RSK. 
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Three ways activation of NF-κΒ by ζPKC: 
ζPKC has been shown to activate NF-κB by phosphorylating IKKβ resulting in 
the phosphorylation and degradation of ΙκB (Sanz et al., 1999). ζPKC can also bind to 
RelA and phosphorylate serine 276 (Leitges et al., 2001) (Anrather et al., 1999). Since 
ζPKC is activated by Ras and it is a partner of Par-4, I decided to look for a possible 
involvement of ζPKC in RelA activation through the TA1 domain. Indeed, over-
expression of a wild type ζPKC was able to increase luciferase expression in response to 
RelA activation. Co-expression of Par-4 and ζPKC abrogates this activation (Fig. 3.12). 
The effect of Par-4 on ζPKC activation can result from direct binding and depletion of 
ζPKC available for RelA phosphorylation; Par-4 may be interfering with a possible 
binding between RelA and ζPKC; or Par-4 binding may inhibit the enzymatic activity of 
ζPKC interfering with its ability to activate RelA. 
 
DISCUSSION 
Inhibition of NF-κB is one of the essential functions of Par-4. It is required for 
Par-4 ability to induce apoptosis and to inhibit transformation (Qiu et al., 1999b) 
(Chakraborty et al., 2001). Despite its importance the exact mechanism of NF-κB 
inhibition by Par-4 is not yet elucidated. There are few clues for possible mechanisms but 
they are either not fully confirmed or can not explain the full effects of Par-4 on NF-κB 
activity. Par-4 binds and inhibits ζPKC, which can affect NF-κB nuclear translocation 
and activation of full length RelA. In my work I chose to study the effect of Par-4 on the 
TA1 domain of RelA. This domain is activated effectively by Ras. Although TNF-α  
causes phosphorylation of serine 529 (Wang and Baldwin, 1998), deletion of TA2 
abrogates activation of RelA by TNF-α. Since ERK was repeatedly implicated in 
activating RelA and it is down-regulated by Par-4, I chose ERK as my first target. I was 
able to show that ERK is involved in activation of RelA by Ras and that inhibition of 
ERK by dnERK will completely block Ras induced RelA activation. 
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Figure 3.12: ζPKC activates RelA by acting on the TA1 domain. Ras NIH 3T3 or 
PC3 cells were transfected with the appropriate plasmids and harvested 48 hours after 
transfection. The prepared lysates were subjected to luciferase activity and β-
galactosidase assays. Results were normalized to β-galactosidase expression. The 
Luciferase activity is represented as relative values where the untreated control value has 
been set to one. 
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Figure 3.12: ζPKC activates RelA by acting on the TA1 domain. 
 
 
 
 134
 
 
Attempting to discover the mechanism of RelA activation by ERK uncovered 
another player. Over-expression of wild type RSK activates the transcriptional activity of 
RelA. Unfortunately, my data could not place RSK downstream of ERK in activating 
RelA. Dominant negative RSK was not as effective as dominant negative ERK in 
inhibiting Ras induced RelA activity. In addition RSK and ERK seems to target different 
sites on RelA. ERK activation requires serine 529 while RSK does not. This data 
suggests that phosphorylation of serine 529 is at least part of the mechanism of RelA 
activation by ERK. On the other hand RSK activation can be directed at the other known 
phosphorylation site in the TA1 domain, serine 536. RSK can be targeting IKKβ, which 
is known to directly phosphorylate S 536 on RelA (Sakurai et al., 1999). 
ζPKC was an ideal molecule to study. It phosphorylates IKKβ resulting in 
increase of NF-κB translocation to the nucleus. It phosphorylates serine 276 in the RHD 
of RelA thus allowing CBP/p300 binding and resulting in activation of RelA. In addition 
to all this, it physically associates with Par-4 and RelA  (Diaz-Meco et al. 1996) (Leitges 
et al., 2001). In addition to the mentioned modes of NF-κB regulation by ζPKC my work 
showed that ζPKC can also activate RelA by acting on the TA1 domain. The ζPKC effect 
can be a direct result of the phosphorylation and activation of IKKβ, which in addition to 
phosphorylating IκB will phosphorylate RelA on S 536. Par-4 inhibits TA1 activation by 
ζPKC. If IKKβ is the real target of ζPKC in both the nucleus and the cytoplasm, than 
inhibition of both pathways can be accomplished by Par-4 binding to ζPKC. 
The ability of Par-4 to inhibit a wide array of RelA activator is a little confusing. 
This may suggest that Par-4 have a general transcription inhibition ability. On the other 
hand, a more specific mode of action would result from a direct binding between Par-4 
and the TA1 domain of RelA, which will then interfere with the phosphorylation of the 
necessary amino acids by a number of different kinases. Binding may also interfere with 
interactions with co-activators involved in RelA TA1 function. A less specific inhibition 
by Par-4 can result from binding and inhibition of other parts of the reporter system 
which is less likely since Par-4 did not inhibit a similar system having Elk in place of 
RelA (Nalca et al., 1999).  
 135
 
If we exclude binding as a mode of inhibition, we can still propose other general 
inhibition mechanisms arising from inhibiting basic transcription machinery in the cell. 
Again I do not think this is the case because Par-4 would then be able to kill any cell by 
inhibiting its transcription and we already know that Par-4 does not kill all cell especially 
normal cells which would be more sensitive to such inhibition. In addition, Par-4 did not 
inhibit the Gal4-Elk activity as shown by Nalca (Nalca et al., 1999). My last argument 
against general inhibition of transcription arises from the use of β-gal for normalization 
of transfection efficiency. Inhibition of transcription would affect the expression of β-gal, 
which is not the case. Par-4 causes a slight to no decrease in β-gal expression. This will 
bring us back to a specific mechanism of inhibition that may involve a yet unknown 
downstream activator of RelA where the above activation pathways converge. Although 
in this scenario, I think Par-4 is affecting multiple molecules to cause its strong inhibition 
on RelA. The functions of Par-4 studied so far favors such mechanism. Par-4 is a pro-
apoptosis protein that induces apoptosis by the activation of multiple pathways. It 
regulates Fas/FasL pathway; it inhibits NF-κB, it binds to WT1 to inhibit Bcl-2 
expression and maybe more unidentified proteins. It binds to and inhibits different 
functions of ζPKC; it has different function in the cytoplasm and nucleus. I think this 
quite broad range of activities can explain the ability of Par-4 to inhibit multiple RelA 
activation mechanisms. 
My data and other published work suggest that some factors activate NF-κB using 
more than one method. IκB phosphorylation, being the best studied, is frequently 
accompanied by activation of RelA by phosphorylation at different sites. My result 
extends this ability to another molecule, RSK. Furthermore, I was able to identify new 
site of action for ζPKC. Finally, I was able to narrow down the possible site of action of 
ERK to amino acid serine 529 of the RelA TA1 domain. 
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CHAPTER 4 
GENERAL DISCUSSION & FUTURE DIRECTIONS 
Par-4 has a nuclear function and nuclear entry is controlled by more than one 
domain: 
The ability of Par-4 to interact with the nuclear protein WT1 and to function as a 
transcription repressor suggested a nuclear function for Par-4. However, studies from 
another group on the interaction with ζPKC suggested that Par-4 is a cytoplasmic protein 
(Diaz-Meco et al., 1996). In these latter studies, the first 60 amino acids of Par-4 were 
deleted with the assumption that NLS1 is the only localization sequence in Par-4. The 
mutant localization was determined in only one cell line, which, in the case of Par-4, 
turns out to be the wrong approach. Our own localization studies presented here, indicate 
that Par-4 localization is related to its ability to induce apoptosis in specific cell lines. 
Par-4 is able to translocate to the nucleus in cell in which it can induce apoptosis. Par-4 
nuclear entry requires NLS2, which is a bipartite sequence located between amino acids 
137 and 153. In the absence of NLS2, Par-4 loses the ability to induce apoptosis in the 
sensitive cell lines (PC3, DU145, LNCaP IGFBP5, Ras NIH3T3). This loss of function is 
partially due to the inability of ∆NLS2 to inhibit NF-κB transactivation. However, the 
nuclear presence of Par-4 may be essential in down modulating other survival pathways. 
One such pathway is Bcl-2, which is down-regulated by Par-4 at the promoter level 
(Cheema et al. 2002). 
The leucine zipper domain of Par-4 is required for binding to ζPKC, WT1, p62 
and Dlk. The ability of ∆Zip, a mutant lacking the leucine zipper domain, to induce 
apoptosis suggests that none of the currently known partners of Par-4 are required for this 
function. The discovery of the putative NES in the leucine zipper region implies that 
some of partner proteins may be involved in regulating Par-4 localization by masking the 
NES and inducing Par-4 nuclear entry. Deletion of the leucine zipper domain, and 
therefore the NES, bypasses the need for protein-protein interaction for localization 
control and results in the dominance of NLS2. Another possibility suggested by this study 
is that other domains of Par-4 may be involved in binding to one or more of its known 
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partners. The third possibility is that one or more of the partners inhibits Par-4 function 
by binding to the leucine zipper domain in a localization-independent manner. 
The studying Par-4 localization revealed that 1) nuclear and cytoplasmic Par-4 are 
required for apoptosis induction, 2) Par-4 translocates to the nucleus only in sensitive cell 
lines and 3) The leucine zipper domain is dispensable for the apoptotic function of Par-4. 
Deletion of the C-end widens the range of Par-4 action 
The importance of Par-4 arises from its ability to induce apoptosis in a number of 
tumor cell lines but not normal cells. Par-4 can kill androgen-independent prostate cancer 
cell lines, which are responsible for treatment refractory metastatic prostate cancer, but 
not androgen-dependent cells. The ability of Par-4 to induce apoptosis in androgen-
independent prostate cancer cell lines requires both inhibition of NF-κB and Fas 
translocation to the membrane. The selectivity in killing specific types of cancer cells 
limits the potential benefit of Par-4 as a therapeutic agent. A possible 
inhibitory/regulatory domain present in C-terminal end of Par-4 that was removed by 
deletion of 128 amino acids of the C-terminus resulted in a protein that has a wider range 
of action. The new protein is able to induce apoptosis and Fas translocation in the 
resistant cell line LNCaP by a mechanism that is not totally clear. Unlike PC3 and Ras 
NIH 3T3 cells, NF-κB is not constitutively active in LNCaP cells (Palayoor et al., 1999), 
which suggests that inhibition of NF-κB may not induce apoptosis of LNCaP cells. In 
addition, increase of Fas translocation alone is not sufficient to induce apoptosis in 
LNCaP (Rokhlin et al., 1997). 204 may be able to kill LNCaP by activating additional 
apoptotic pathways. Indeed, co-transfection of Fas and Par-4 kills LNCaP (data not 
shown) suggesting that Par-4 is able to induce certain apoptotic pathway that cooperates 
with Fas to kill LNCaP cells. Perhaps, this same pathway may be used by 204 to induce 
apoptosis in LNCaP cells. Alternatively, 204 may have the ability to translocate FasL 
together with Fas. This may be enough to kill the LNCaP cells since it has been shown 
that, although LNCaP is not sensitive to killing by anti-Fas antibodies like CH-11 or the 
extracellular soluble FasL, increase in intracellular FasL results in 70-98% apoptosis in 
48 hours (Hyer et al., 2000). 
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A core of 67 amino acids is sufficient to induce apoptosis 
Deletion analysis revealed that the functional domain of Par-4 is a central core 
that contains the nuclear localization sequence and is almost totally conserved between 
humans, rats and mice. There are two other highly conserved region in Par-4: one in the 
N-terminus around NLS1 and the second at the C-end, which includes the leucine zipper 
domain and the NES. Deletion of the C and N conserved region does not interfere with 
apoptotic function of Par-4, on the contrary, it enhances its activity against previously 
resistant cancer cells. This strongly suggests that the C and N conserved regions are 
involved in regulation of Par-4 functions, and thus may explain why the constitutive 
presence of intact Par-4 in cancer normal cells does not result in apoptosis. The 
identification of such a domain with selective ability to induce apoptosis in cancer but not 
normal cells may facilitate the use of Par-4 properties in cancer therapy.  
ERK and RSK act on the TA1 domain of RelA independently 
An essential component of apoptosis induction by Par-4 is inhibition of NF-κB 
and RelA activities. During my work with Par-4 mutants, there was always a correlation 
between the ability to inhibit RelA transactivation and induction of apoptosis. 
Unfortunately, the mechanism of inhibition of RelA transcription activity is still a 
mystery. Although my attempts to elucidate this mechanism were not conclusive, I 
discovered several new elements in the complicated process of regulating RelA 
transactivation. ERK, RSK and ζPKC all have known role in NF-κB activation. The role 
of ζPKC is much more characterized than the other two kinases. It phosphorylates IKKβ 
results in degradation of IκB and release of NF- κB, in addition it enhances the 
transcriptional activity of RelA by phosphorylating it on serine 276 in the RHD (Anrather 
et al., 1999). I have showed that ζPKC can also enhance the activity of the TA1 (519-521 
aa) region of RelA. The TA1 domain requires phosphorylation at serines 526 and 536 for 
activation. ζPKC effect on the TA1 activation may be the result of a direct 
phosphorylation of one or both serines. Alternatively, ζPKC may be affecting another 
kinase that is phosphorylating the serines. IKKβ is a likely candidate since it is a ζPKC 
substrate and is known to phosphorylate TA1 (Moscat and Diaz-Meco, 2000, Sakurai et 
al., 1999).  
 139
 
The roles of ERK and RSK are less clear. ERK enhances NF-κB activity probably 
by its effect on RelA transcription activation. The exact mechanism is not known but it 
has been shown repeatedly that inhibition of the ERK pathway by the MEK inhibitor 
PD98059 inhibits NF-κB activated by TNF-α, okadaic acid and other agents 
(Birkenkamp et al., 2000; Hoshi et al., 2000; Vanden Berghe et al., 1998). On the other 
hand, one report suggests that a constitutive active MEK-ERK pathway negatively 
regulates NF-κB activities (Carter and Hunninghake, 2000). In my hands, ERK strongly 
activates the TA1 domain of RelA in PC3 human cells and in Ras NIH 3T3 mouse cells. 
Inhibition of ERK using PD98059 or a dominant negative expression vector of ERK2 
strongly inhibits RelA activity. My attempts to place RSK downstream of ERK in 
activation of RelA failed. RSK is known to activate NF-κB by phosphorylating IκBα 
(Schouten et al., 1997). RSK is traditionally considered to be ERK's substrate, which is 
expected considering that in Xenopus laevis oocytes, as much as 50% of the total pool of 
ERK2 is complexed with RSK (Hsiao et al., 1994). Contrary to my expectations, ERK 
and RSK activate RelA independently. Although the action of these kinases have been 
narrowed down to the TA1 domain, further analysis is required to determine the 
mechanism of activation, which will most probably involve phosphorylation of serines 
529 and/or 536 and the question will be, is the phosphorylation direct or indirect. 
The progress made in the elucidation of the mechanism of inhibition of RelA by 
Par-4 raised more questions since three different activating pathways are inhibited by 
Par-4. Whether Par-4 inhibits each of the three kinases individually or a common 
downstream substrate, is an open question. Par-4 is known to affect two of the kinases: it 
down-regulates ERK and it binds to and inhibits ζPKC. If ζPKC does not bind to a 
domain other than the leucine zipper, the existence of a common downstream target of 
Par-4 should provide a better explanation of RelA inhibition by Par-4 and its C-terminus 
mutants. 
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Future Direction 
Characterization of the NES 
Detailed characterization of the putative NES is an essential part of understanding 
the mechanism of regulation of Par-4. I already know that its presence is not essential for 
Par-4 function in apoptosis, but I would like to know how it is working by identifying the 
essential amino acids in the NES and identifying proteins and exportins that binds to it 
thus resulting in transporting Par-4 to the cytoplasm. Identification of the proteins 
interacting to the NES may shed some new light on the mechanism of resistance of some 
cells to Par-4 killing. 
Identifying the mechanism of regulation of Par-4 
Par-4 is an apoptotic protein that is expressed in almost all cell types but remains 
generally inactive. Its over-expression may overcome the need for its activation. It is 
crucial to understand the mechanism of Par-4 activation because it can then be artificially 
induced as part of cancer therapy. Being a cancer specific apoptotic protein, a systemic 
activation of Par-4 should, at least theoretically, have very little side effects. In addition, 
the mechanism of Par-4 activation will help in clarifying its role in neurodegenerative 
diseases, and inhibition of Par-4 may thus provide a target for therapies to decrease the 
detrimental effects of neuronal apoptosis.  
There are numerous potential points for regulation of Par-4 molecule. Deletion 
analysis strongly points towards the C-terminus as a main regulatory domain, but other 
conserved phosphorylation sites situated at key positions such as around NLS2, seem 
important targets for regulation. Finally, the short conserved region in the N-terminus 
may be a potential regulatory domain since its deletion results in increased apoptosis and 
RelA inhibition.  
Par-4 regulation will most probably turn out to be quite complex. Its function is 
regulated by localization, which may be affected by binding to other proteins, and by 
phosphorylation. Par-4 may also be regulated by protease cleavage, since Western blots 
probed with anti-Par-4 antibodies show reproducible bands smaller than Par-4 that seem 
to be the product of systematic cleavage (data not shown). Sequencing of some of these 
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bands will reveal the positions of cleavage and may help in understanding their role in the 
regulation of Par-4 function. 
Mechanism of NF-κB inhibition 
Despite the advances made in the elucidation of Par-4 complex mechanisms in 
inhibiting NF-κB and RelA activation, there is still much to be studied. The elucidation 
of the mechanism of RelA inhibition should answer the following questions: Is Par-4 
targeting the ERK, RSK and ζPKC pathways individually or targeting a common 
downstream molecule where they all converge? Does Par-4 bind to the TA1 domain of 
RelA? Does Par-4 have a role in the general transcription machinery?  
The C-terminus Par-4 mutant 204 is as efficient as Par-4 itself in inhibiting NF-
κB activity, which cannot be explained by binding ζPKC through the leucine zipper 
domain. If the presence of a new binding domain in Par-4 is ruled out, a new Par-4 target 
involved in NF-κB inhibition must exict. 
Mechanism of Fas regulation. 
Par-4 is able to induce Fas and FasL translocation to the membrane in cell lines in 
which it can induce apoptosis. My work suggests that cytoplasmic Par-4 is sufficient to 
affect Fas/FasL regulation and that the sequence between 204 to 265 is involved in 
regulating this aspect of Par-4 function. On the other hand, the exact mechanism by 
which Par-4 causes Fas/FasL trafficking is unknown and needs detailed analysis. Another 
important question to be addressed is a possible role for Par-4 in regulating other death 
receptors.  
Therapeutic possibilities. 
Par-4 represents an excellent candidate for gene therapy because unlike other pro-
apoptotic proteins, Par-4 does not kill normal cells. In my studies, I was able to construct 
a relatively small derivative of Par-4 that does a better job: it kills more cancer cell lines 
and still spares the normal cells. The small size of this cancer killer protein may facilitate 
the task of designing a vector for gene therapy. Moreover, the selective ability in killing 
cancer cells decreases the need for a precise targeting mechanism for the carrier.  
 142
 
APPENDIX  
LIST OF ABBREVIATIONS 
 
AD: Alzheimers disease. 
ALS: Amyotrophic lateral sclerosis. 
αMEM: Minimum essential medium. 
ANK: ankyrin repeat. 
ATRA: all trans-retinoic acid. 
βAPP: Beta amyloid precursor protein. 
BP5: Binding protein 5. 
cFLIP: FLICE inhibitory protein.  
CKII: Casein kinase II. 
DAP kinase: death associated protein 
kinase. 
DAPI: 4',6'-diamidino-2-phenylindole 
hydrochloride. 
DISC: death inducing signaling complex. 
Dlk: DAP-like kinase  
DMEM: Dulbeco's modified Eagle 
medium. 
DTT: dithiothreitol. 
ERK: Extracellular Signal-Regulated 
kinase. 
FADD: Fas associated death domain 
protein. 
FasL: Fas ligand. 
FBS: fetal bovine serum. 
FLICE: FADD like ICE (caspase 8).  
GFP: Green fluorescence protein. 
HEPES: N-2-hydroxyethylpiperazine N'-
2-ethanesulfonic acid. 
HIV: Human immunodeficiency virus 
IAPs: Inhibitor of Apoptosis Proteins. 
IGF: Insulin growth factor. 
IKK: IκB kinase. 
IL-1: Interleukine-1 
IPTG: isopropyl-beta-D-
thiogalactopyranoside 
IκB: inhibitor of κB. 
kDa: kilodalton 
LB: Luria broth. 
MPTP: 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine. 
NES: Nuclear exclusion sequence. 
NF-κB: Nuclear factor-κB 
NLS: Nuclear localization sequence. 
Par-4: Prostate apoptosis response 4. 
PBS: phosphate buffered saline 
PCR: Polymerase chain reaction. 
PI: Propidium iodide 
PKA: Protein kinase A. 
PKC: Protein kinase C. 
PML: Promyelocytic leukemia. 
PSD: postsynaptic density. 
PVDF: Polyvinylidene difluoride. 
RCC: Renal cell carcinomas. 
RHD: Rel homology domain. 
RIP: Receptor-interacting protein. 
RSK: Ribosomal S6 kinase. 
SDS: sodium dodecylsulfate. 
SDS-PAGE: sodium dodecylsulfate 
polyacrylamide gel electrophoresis. 
TA1: Transactivation domain 1. 
TNF-α: Tumor necrosis factor alpha. 
TNF-R: TNF receptor. 
TUNEL: terminal deoxynucleotide 
transferase-mediated dUTP-biotin nick 
end labeling. 
WT1: Wilms' tumor 1. 
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